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A Helper for Patenting the
“Unpredictable”: Artificial Intelligence
Shuang Liu*
INTRODUCTION
A patent is a limited-term exclusive right over a claimed
invention.1 In return for this exclusive right, society obtains not
just a new piece of “art,”2 but also “the technological know-how
behind the inventor’s patent.”3 Therefore, it is an “indispensable
condition in all patents, that the patentee4 shall ascertain the
nature of his invention, and in what manner it is to be
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1. “A patent is not the grant of a right to make or use or sell. It does not,
directly or indirectly, imply any such right. It grants only the right to exclude
others.” Herman v. Youngstown Car Mfg. Co., 191 F. 579, 584 (6th Cir. 1911);
see also 35 U.S.C. § 271. In the United States, the patent term for a utility
patent is twenty years, 35 U.S.C. § 154(a)(2), for a design patent fifteen years,
35 U.S.C. § 173, and for a plant patent twenty years. 35 U.S.C. § 161 (“The
provisions of this title relating to patents for inventions shall apply to patents
for plants, except as otherwise provided.”).
2. In the context of patent law, the term “art” is often used as a synonym
for “technology.” This Note uses “art” in the same way.
3. ROBERT P. MERGES & JOHN F. DUFFY, PATENT LAW AND POLICY 247
(7th ed. 2017).
4. A patentee, also an assignee, is a person or entity that holds a patent
right. See 35 U.S.C. § 100(d) (1952). Relatedly, an applicant is a person or entity
that applies for a patent. See 37 C.F.R. § 1.42(a). An inventor is a person who
invents what is sought to be patented. See 35 U.S.C. § 100(f) (1952). Although
the patentee/assignee, applicant, and inventor can be different for a given
patent, this Note uses these terms equivalently to avoid unnecessary
complexity.
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performed.”5 This “indispensable condition” is embedded in the
enablement requirement and the written description
requirement under 35 U.S.C. § 112(a):
The specification6 shall contain a written description of the invention,
and of the manner and process of making and using it, in such full,
clear, concise, and exact terms as to enable any person skilled in the
art to which it pertains, or with which it is most nearly connected, to
make and use the same . . . .7

For the purpose of patent law, “the invention” is the claim. 8
Claims define the “metes and bounds” of the patentee’s
intellectual property.9 It is against the full scope of claims that
the patentee is required to provide a sufficient disclosure
satisfying
the
enablement
and
written
description
requirements.10 That is, for a claim to be valid, among other
requirements, the patent document must contain enough
disclosure such that “a person having ordinary skill in the art”
(PHOSITA)11 is able to recognize what the patentee claims as

5. THOMAS G. FESSENDEN, AN ESSAY ON THE LAW OF PATENTS FOR NEW
INVENTIONS 48–49 (1st ed. 1810); see also Pfaff v. Wells Elecs., Inc., 525 U.S.
55, 63 (1998) (“[T]he patent system represents a carefully crafted bargain that
encourages both the creation and the public disclosure of new and useful
advances in technology, in return for an exclusive monopoly for a limited period
of time.”).
6. Under 35 U.S.C. § 111(a)(2) (1952), a patent application shall include a
specification, a drawing, and an inventor’s (or inventors’) oath or declaration.
The specification usually includes sections of abstract, background, summary of
invention, detailed description of invention, and claims. See MPEP § 608.01 (9th
ed. Rev. 10.2019, June 2020). An applicant commonly describes the invention
in the summary of invention and detailed description of invention sections with
drawings, if any.
7. 35 U.S.C. § 112(a) (1952) (emphasis added).
8. See Jones v. Hardy, 727 F.2d 1524, 1528 (Fed. Cir. 1984) (“[E]ach claim
must be considered as defining a separate invention.” (citation omitted)).
9. In re Vamco Mach. & Tool, Inc., 752 F.2d 1564, 1577 n.5 (Fed. Cir. 1985)
(“The function of claims is (a) to point out what the invention is in such a way
as to distinguish it from what was previously known, i.e., from the prior art;
and (b) to define the scope of protection afforded by the patent. In both of those
aspects, claims are not technical descriptions of the disclosed inventions but are
legal documents like the descriptions of lands by metes and bounds in a deed
which define the area conveyed but do not describe the land.” (emphasis added)).
10. See In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993) (“Although not
explicitly stated in [35 U.S.C. §] 112, to be enabling, the specification of a patent
must teach those skilled in the art how to make and use the full scope of the
claimed invention without ‘undue experimentation.’” (emphasis added)
(citations omitted)).
11. A PHOSITA is a “hypothetical person who is presumed to be aware of
all the pertinent prior art.” Custom Accessories, Inc. v. Jeffrey-Allan Indus.,
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the invention, to practice12 the full scope of the claimed
invention, and to see that the patentee has actually made the
invention, or is in “possession” of it. 13
However, for technologies of different nature, the required
amounts of disclosure for enablement purposes are in sharp
distinction. As the Fisher court famously stated:
In cases involving predictable factors, such as mechanical or electrical
elements, a single embodiment14 provides broad enablement in the
sense that, once imagined, other embodiments can be made without
difficulty and their performance characteristics predicted by resort to
known scientific laws. In cases involving unpredictable factors, such
as most chemical reactions and physiological activity, the scope of
enablement obviously varies inversely with the degree of
unpredictability of the factors involved.15

By the same token, the required amount of disclosure for
showing possession of an invention varies by arts.16 For example,
consider a scenario where a patentee invents a machine
comprising a connection component and describes the connection
component by a nail. The patentee is then obviated from
describing a machine comprising a screw as the connection
component but can still show that he or she has invented17 such
Inc., 807 F.2d 955, 962 (Fed. Cir. 1986) (citation omitted). See infra Section
I.A.1.b for details.
12. In the context of patent law, “practicing a claim” generally means
making and using a claim. This Note uses the phrase in the same way.
13. In re Kaslow, 707 F.2d 1366, 1375 (Fed. Cir. 1983) (“The test for
determining compliance with the written description requirement is whether
the disclosure of the application as originally filed reasonably conveys to the
artisan that the inventor had possession at that time of the later claimed subject
matter, rather than the presence or absence of literal support in the
specification for the claim language.” (emphasis added) (citations omitted)).
14. In the context of patent law, the term “embodiment” usually refers a
concrete example of an invention. See Tom Brody, Preferred Embodiments in
Patents, 9 J. MARSHALL REV. INTELL. PROP. L. 398, 398 (2009) (“It is a tradition
in patent drafting to refer to . . . examples as . . . ‘embodiment[s].’”).
15. In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970).
16. See Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed.
Cir. 2010) (“Specifically, the level of detail required to satisfy the written
description requirement varies depending on the nature and scope of the claims
and on the complexity and predictability of the relevant technology.” (citation
omitted)).
17. Under patent law, an invention is made when there is a conception and
a reduction to practice. Dunn v. Ragin, 50 U.S.P.Q. 472, 474 (B.P.A.I. 1941).
“The conception of the invention consists in the complete performance of the
mental part of the inventive art . . . . It is . . . the formation in the mind of the
inventor of a definite and permanent idea of the complete and operative
invention . . . .” Townsend v. Smith, 36 F.2d 292, 295 (C.C.P.A. 1929). Reduction
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a machine. In contrast, consider another hypothetical in which
a patentee invents a new drug for a disease X, and the drug
comprises a main structure M and an element A attached to the
main structure. The patentee cannot declare to the public that
he or she has also invented a drug comprising the main structure
M and an element B without disclosing it in the specification.
After all, changing one element of a drug might render it no
longer effective for its purpose and even cause unintended
effects.18 Accordingly, the patentee in the first example is able to
support a claim of “a machine comprising a connection
component” by describing the machine with a nail as the
connection component, but the patentee in the second example
is unable to support a claim of “a drug comprising a main
structure M and an element” by providing the experiment
results of only the compound with element A attached to the
main structure M.19 It is then obvious that the enablement and
written description requirements are posing more difficulties for
“genus claims”20 in unpredictable arts than predictable arts to
to practice may be an actual reduction or a constructive reduction to practice.
Dunn, 50 U.S.P.Q. at 472. Establishing “an actual reduction to practice
[requires] (1) the [applicant to] construct[] an embodiment or perform[] a
process that [meets] every element of the interference count, and (2) the
embodiment or process [to] operate[] for its intended purpose.” Eaton v. Evans,
204 F.3d 1094, 1097 (Fed. Cir. 2000). In contrast, a constructive reduction to
practice can be done by filing a patent application which satisfies the
enablement and written description requirements. Hyatt v. Boone, 146 F.3d
1348, 1352 (Fed. Cir. 1998). Accordingly, in this hypothetical scenario, the
patentee has “invented” the machine comprising a screw by a conception and a
constructive reduction to practice.
18. See, e.g., Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149, 1155
(Fed. Cir. 2019) (“[I]n the nucleoside area[, a specific type of chemicals,] . . . the
smallest change can have a dramatic effect not only on the activity of that
compound but on the toxicity of the compound. So nothing is predictable.”
(quotation mark omitted) (citation omitted)).
19. See infra notes 145–47 and accompanying text for real cases presenting
this issue.
20. A genus claim, also called a “generic claim,” is a claim that covers more
than one species, where the “generic claim should require no material element
additional to those required by the species claims, and each of the species claims
must require all the limitations of the generic claim.” MPEP § 806.04(d) (9th ed.
Rev. 10.2019, June 2020). Specifically, in the first one of preceding examples,
the genus claim is “a machine comprising a connection component,” and a
species claim is “a machine comprising a connection component, wherein the
connection component is a nail”; similarly, in the second example, the genus
claim is “a drug for a disease X, comprising a main structure M and an element,”
and a species claim is “a drug for a disease X, comprising a main structure M
and an element, wherein the element is A.”
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stand valid before either the Patent and Trademark Office (PTO)
or courts.21
A potential response to this difficult situation is to claim
narrowly: if the claim covers only one species that is fully
described by the embodiments, it will undoubtedly meet the
enablement and written description requirements. But a patent
is only valuable in the context of business.22 Narrow claims
afford only a weak protection to a patentee because a competitor
can easily find variations of the patentee’s inventions without
infringing the narrowly-claimed patents. 23 This problematic
reality compels patent applicants to claim broadly, even as the
PTO and courts are making such practice harder and harder.24
Another solution to this dilemma is to invent the genus—
that is, to not only conceive how to obtain the species of the
genus, but also know what the species are.25 This solution might
sound trivial because, if an applicant can afford the time and
money to experiment with every species in the entire genus, the
problem posed above should have not existed to begin with. But
this solution is actually practical because it is possible to invent

21. See Sean B. Seymore, Heightened Enablement in the Unpredictable
Arts, 56 UCLA L. REV. 127, 136–37 (2008).
22. See Michael K. Henry, Claim Strategies for Patent Applications: Can
Your Patent Claims Ever Be Too Narrow?, HENRY (Dec. 7, 2017), https://henry.
law/blog/can-your-patent-claims-ever-be-too-narrow/ (“Patents are, first and
foremost, business tools. They can help protect your invention’s commercial
value or offer your business an advantage over its competitors.”); see also Joan
Farre-Mensa et al., What Is a Patent Worth? Evidence from the U.S. Patent
“Lottery”, 75 J. F IN. 639, 639 (2020) (“In theory, patents can benefit their holders
by deterring copycats and by serving as defensive shields in litigation suits, as
bargaining chips in licensing negotiations, and as signaling devices to attract
investors and customers.”).
23. See Quality Patents: Claiming What Counts, WIPO MAG., Jan./Feb.
2006, at 17, 18 (“[B]road claims are attractive to the business applicant because
they cover a greater range of products or situations . . . . Conversely, [narrow
claims] will prove less useful as a business tool since they allow competitors to
gain easy access to the same market by producing products with only minor
modifications to the patented product or service.”); see also Henry, supra note
22.
24. See generally Dmitry Karshtedt et al., The Death of the Genus Claim,
35 HARV. J.L. & TECH. 1 (2021).
25. If an applicant is able to describe (1) what the species are, and (2) how
to make and use them, the applicant will be able to file an application that
satisfies the enablement and written description requirement, and thereby
constructively reduce the invention. See supra note 17. In this sense, the
applicant invents the genus by a conception and a constructive reduction to
practice. See id.
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the whole genus without experimenting with all species covered
by it. The secret for doing so is Artificial Intelligence (AI).
AI is generally understood as a machine simulating human
thinking and actions in response to a situation.26 Many modern
inventions are made possible by AI, such as language recognition
(e.g., Siri27 and Alexa28), smart recommendations (e.g., TikTok,29
YouTube,30 and Amazon 31), and self-driving cars (e.g., Tesla32).
Scientists are also developing AI for research purposes. For
example, Naik et al. developed an AI for predicting whether a
given drug has some effects on a given protein.33 Once fed with
26. There is no universal definition of AI. The concept of AI stemmed from
the seminal work, Alan M. Turing, Computing Machinery and Intelligence, 59
MIND 433 (1950), in which Dr. Turing proposed a test for telling whether a
machine possessed intelligence (now famously known as the “Turing Test”).
Upon the pass of the Turing test, a machine can be said to possess intelligence.
Id. at 433–34. Later, Dr. McCarthy provided a definition of AI: “It is the science
and engineering of making intelligent machines, especially intelligent computer
programs. It is related to the similar task of using computers to understand
human intelligence, but AI does not have to confine itself to methods that are
biologically observable.” JOHN MCCARTHY, WHAT IS ARTIFICIAL INTELLIGENCE?
2 (2004). In a classical AI textbook, Dr. Russell and Dr. Norvig summarized
various definitions of AI, all of which are related to a machine thinking and/or
acting humanly and/or rationally. STUART J. RUSSELL & PETER NORVIG,
ARTIFICIAL INTELLIGENCE: A MODERN APPROACH 2 (3d ed. 2010).
27. See, e.g., William Goddard, Is Siri AI?, ITCHRONICLES (Nov. 23, 2020),
https://itchronicles.com/artificial-intelligence/is-siri-ai/ (“Siri is a system that
uses artificial intelligence . . . .”).
28. See, e.g., What Is Conversational AI?, ALEXA, https://developer.amazon.
com/en-US/alexa/alexa-skills-kit/conversational-ai (last visited Jan. 12, 2022)
(“With conversational AI, voice-enabled devices like Amazon Echo are enabling
the sort of magical interactions we’ve dreamed of for decades.”).
29. See, e.g., Catherine Wang, Why TikTok Made Its User So Obsessive? The
AI Algorithm That Got You Hooked, TOWARDS DATA SCI. (June 7, 2020),
https://towardsdatascience.com/why-tiktok-made-its-user-so-obsessive-the-aialgorithm-that-got-you-hooked-7895bb1ab423.
30. See, e.g., Aratrika Dutta, How Does Youtube Algorithm Work? The Use
of AI for Video Recommendations, ANALYTICS INSIGHT (Oct. 21, 2021), https://
www.analyticsinsight.net/how-does-youtube-algorithm-work-the-use-of-ai-forvideo-recommendations/.
31. See, e.g., 3 Ways Amazon Uses AI to Make Product Recommendations,
LINEATE (Dec. 16, 2019), https://www.lineate.com/technology-insights/3-waysamazon-uses-ai-to-make-product-recommendations.
32. See, e.g., Artificial Intelligence & Autopilot, TESLA, https://www.tesla.
com/AI (last visited Jan. 12, 2022) (“We believe that an approach based on
advanced AI for vision and planning, supported by efficient use of inference
hardware, is the only way to achieve a general solution for full self-driving and
beyond.”).
33. Armaghan W. Naik et al., Active Machine Learning-Driven
Experimentation to Determine Compound Effects on Protein Patterns, ELIFE,
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initial proteins and drugs, the AI operates to determine what
combinations of proteins and drugs it needs to experiment with
to allow or improve its predictions. 34 It then performs
experiments with its liquid-handling robotics and repeats the
determination-experimentation cycle until the end condition set
by the developers is triggered.35 In an attempt to predict the
effects forty-eight different drugs would have on forty-eight
different proteins, the AI experimented with 29% of all possible
combinations36 and reached a 92% prediction accuracy.37
Similarly, AI with impressive prediction capabilities have
emerged for many other applications, including predicting
myriad structures and properties of existing or prospective
materials, 38 potency and other properties of drug candidates,39
de novo materials40 and drugs41 for given purposes, new uses of
FDA-approved drugs,42 and promising synthesis routes for
drugs.43
These inspiring results highlight the plausibility for patent
practitioners to file claims within the capability of a welldeveloped AI—claims that are broader than just one or two
experimentally-confirmed species but narrow enough to be
enabled and described by the AI predictions. Accordingly, this
Note discusses how applicants can utilize AI to file genus claims
in the traditionally unpredictable arts and experiment with only
a few species, while minimizing risks of enablement and written
description challenges.
The interaction between AI and patent law has been
discussed by a few scholars.44 Most relevantly, Ebrahim
Feb. 3, 2016, at 1, 2 (“[O]ur goal is to identify whether a given drug perturbs the
pattern of a given protein, and symmetrically, which drugs perturb which
proteins in a similar manner.”).
34. Id. at 3–4.
35. Id.
36. In this work, Naik et al. duplicated each drug and each protein, but the
duplication was not revealed to the AI. Id. Therefore, there were 96 x 96 = 9,216
combinations in total. Id. at 3.
37. Id. at 7 fig. 2.
38. See infra note 202.
39. See infra Section II.B.1.
40. See infra note 203.
41. See infra Section II.B.2.a.
42. See infra Section II.B.2.b.
43. See infra Section II.B.3.
44. See, e.g., Russ Pearlman, Recognizing Artificial Intelligence (AI) as
Authors and Inventors Under U.S. Intellectual Property Law, 24 RICH. J.L. &

678

MINN. J.L. SCI. & TECH.

[Vol. 23:2

discussed the challenges posed by computation-based
simulation45
and
machine-learning-based
prediction46
(collectively, “computational experiments”) in the traditionally
unpredictable arts.47 Specifically, Ebrahim argued that
computational experiments “can enable an inventor to make a
patent application appear as if experimental data has been
achieved when, in fact, there have been only computational
simulations of hypothetical experiments,” 48 and in response, the
PTO and courts should strengthen the utility requirement and
make experiment-based working examples a necessary part of
disclosure
for
computational-experiment-based
patent
applications.49 In contrast, this Note focuses on how patent
practitioners can properly utilize AI predictions to satisfy the
enablement and written description requirements under current
patent law. More particularly, this Note discusses various AIassisted patent practices that take into account the concrete
facts of AI predictions, including what specific areas AI can
make satisfactory prediction and how accurate those predictions
are.50 This Note also briefly explains how to provide a disclosure
that meets the enablement and written description
requirements, and how much experimentation is needed for that
TECH. 2 (2018); Rachel L. Schwein, Patentability and Inventorship of AIGenerated Inventions, 60 WASHBURN L.J. 561 (2021); Lucas R. Yordy, The
Library of Babel for Prior Art: Using Artificial Intelligence to Mass Produce
Prior Art in Patent Law, 74 VAND. L. REV. 521 (2021); Daria Kim, ‘AI-Generated
Inventions’: Time to Get the Record Straight?, 69 GRUR INT’L 443 (2020); Tabrez
Y. Ebrahim, Computational Experimentation, 21 VAND. J. ENT. & TECH. L. 591
(2019).
45. Computation-based simulation is an approach in which molecular
properties can be computed according to established scientific models. See infra
note 152.
46. Machine learning is a major portion of currently available AI. See infra
notes 153–154 and accompanying text.
47. Ebrahim, supra note 44, at 593.
48. Id. at 607.
49. See id. at 613–49. This Note does not endorse this argument by quoting
and paraphrasing it. An applicant cannot “make a patent application appear as
if experimental data has been achieved” when no real experimentation has been
performed without committing “inequitable conduct,” which would render a
patent unenforceable. See, e.g., J.P. Stevens & Co. v. Lex Tex Ltd., Inc., 747 F.2d
1553, 1559 (Fed. Cir. 1984) (“[Inequitable conduct] includes failure to disclose
material information, or submission of false material information, with an
intent to mislead.”). Alternatively, if the applicant is honest and reveals the
examples are prophetic, then such examples are nothing special and can be
readily handled by current law. See infra text accompanying notes 96–97.
50. See infra Sections III.A.1–2.
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purpose.51 In addition, this Note discusses the potential negative
effects of AI predictions on obviousness challenges and provides
suggestions for overcoming them in practice.52
This Note proceeds in three parts. Part I surveys the current
case law on the enablement and written description
requirements in detail. Part II briefly introduces (1) the work
principles of AI, (2) the applications of AI in the traditional
unpredictable arts, especially in drug discovery, and (3) the
accessibility and limitations of AI. Part III describes several AIassisted patent practices and specifically recommends one of
them. It goes on to present the incapability of current patent law
to deal with some problems posed by AI-assisted patent practice,
followed by some proposed solutions. Finally, it defends the AIassisted patent practice from a policy perspective and proposes
a solution to a potential equity concern raised by the
inaccessibility of some AI resources.
I. CASE LAW ON THE ENABLEMENT AND WRITTEN
DESCRIPTION REQUIREMENTS
To perceive how AI predictions can help satisfy the
enablement and written description requirements, an in-depth
understanding of current law on these two issues will be very
helpful. Accordingly, this Section discusses the law related to
these two requirements in detail.
Procedurally, the enablement and written description
requirements, among other requirements, play a role when the
PTO examines a patent application and when a patent is
challenged before the Patent Trial and Appeal Board (PTAB) or
courts. Therefore, an application needs to satisfy the enablement
and written description requirements to become a patent, and a
patent must satisfy these requirements to maintain its validity
when challenged.53 The case law discussed in this Section
includes those before the PTAB,54 the Federal Circuit Court55

51. See id.
52. See infra Section III.A.3.
53. 35 U.S.C. § 112(a).
54. The Board of Patent Appeals and Interferences (BPAI) is the
predecessor of the PTAB. This Note discusses the cases before the BPAI
equivalently as those before the PTAB.
55. The United States Court of Customs and Patent Appeals (CCPA) is the
predecessor of the Federal Circuit Court with respect to the jurisdiction over
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and the U.S. Supreme Court, all of which bind the PTO and are
thus also applicable to the patent examination process. 56 Rules
and guidance from the PTO are also cited; these rules and
guidance bind the examiners only,57 but courts do refer to them
when found to be persuasive.58
A. THE ENABLEMENT REQUIREMENT
To satisfy the enablement requirement under 35 U.S.C.
§ 112, “the specification must teach those skilled in the art how
to make and use the full scope of the claimed invention without
‘undue experimentation.’”59 Hence, enablement issues arise
when the scope of the claim is broader than the guidance
provided by the specification and a PHOSITA is unable to fill the
“gap” without “undue experimentation.” 60 How much
experimentation counts as “undue” is “a matter of degree”;61 it is
determined by the factors established by the Federal Circuit
Court in In re Wands (hereinafter the Wands factors).62
1. The Wands Factors
The Wands factors include:
patent-related cases. This Note discusses the cases before the CCPA
equivalently as those before the Federal Circuit Court.
56. See 35 U.S.C. § 144 (“The United States Court of Appeals for the
Federal Circuit shall review the decision from which an appeal is taken on the
record before the Patent and Trademark Office.”).
57. It is controversial whether the PTAB is bound by the PTO’s guidance.
See Kevin E. Noonan, Who’s in Charge Here? Or Is the PTAB Bound by USPTO
Guidances?, PATENT DOCS (Feb. 19, 2018), https://www.patentdocs.org/2018/02
/whos-in-charge-here-or-is-the-ptab-bound-by-uspto-guidances.html.
58. See In re Fisher, 421 F.3d 1365, 1372 (Fed. Cir. 2005) (concluding that
even though the PTO’s guidance “govern[s] [the USPTO’s] internal practice[s]”
and the USPTO “incorporated these guidelines into the [MPEP],” “[t]he MPEP
and Guidelines are not binding on this court” but they “may be given judicial
notice to the extent they do not conflict with the statute”); see also In re Biogen
‘755 Patent Litigation, 335 F. Supp. 3d 688, 734 (D.N.J. 2018) (“While not
binding on this Court, the PTO’s guidance is nevertheless persuasive.”).
59. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993).
60. See AK Steel Corp. v. Sollac, 344 F.3d 1234, 1244 (Fed. Cir. 2003) (“That
is not to say that the specification itself must necessarily describe how to make
and use every possible variant of the claimed invention, for the artisan’s
knowledge of the prior art and routine experimentation can often fill gaps,
interpolate between embodiments, and perhaps even extrapolate beyond the
disclosed embodiments, depending upon the predictability of the art.”).
61. PPG Indus., Inc. v. Guardian Indus. Corp., 75 F.3d 1558, 1564 (Fed.
Cir. 1996).
62. In re Wands, 858 F.2d 731 (Fed. Cir. 1988).
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(1) [T]he quantity of experimentation necessary, (2) the amount of
direction or guidance presented, (3) the presence or absence of
working examples, (4) the nature of the invention, (5) the state of the
prior art, (6) the relative skill of those in the art, (7) the predictability
or unpredictability of the art, and (8) the breadth of the claims.63

These will be elaborated upon with relevant factors grouped
together.
a. Scope of Claims
Although listed last in the Wands factors, determination of
the scope of claims should actually be the first step of the
enablement analysis. 64 A claim is given a scope of “its broadest
reasonable construction in light of the specification of the
application or patent in which it appears” (hereinafter the BRI
standard)65 during patent examination, 66 and a scope of the
claim “would have to a [PHOSITA] at the time of the invention”
(hereinafter the Phillips standard)67 in post-issuance
procedures.68 While the BRI standard may possibly render a
63. Id. at 737 (citation omitted).
64. See MPEP § 2164.08 (9th ed. Rev. 10.2019, June 2020) (“All questions
of enablement are evaluated against the claimed subject matter . . . .
Accordingly, the first analytical step requires that the examiner determine
exactly what subject matter is encompassed by the claims.”); see also supra note
10 and accompanying text.
65. “Under a broadest reasonable interpretation (BRI), words of the claim
must be given their plain meaning, unless such meaning is inconsistent with
the specification. The plain meaning of a term means the ordinary and
customary meaning given to the term by those of ordinary skill in the art at the
time of the invention. The ordinary and customary meaning of a term may be
evidenced by a variety of sources, including the words of the claims themselves,
the specification, drawings, and prior art.” MPEP § 2111.01.I (9th ed. Rev.
10.2019, June 2020).
66. Koninklijke Philips Elecs. N.V. v. Cardiac Sci. Operating Co., 590 F.3d
1326 (Fed. Cir. 2010).
67. Phillips v. AWH Corp., 415 F.3d 1303, 1313 (Fed. Cir. 2005) (en banc).
68. See Changes to the Claim Construction Standard for Interpreting
Claims in Trial Proceedings Before the Patent Trial and Appeal Board, 83 Fed.
Reg. 21,221-1, 21,223-2 (Oct. 11, 2018) (“This proposed change would replace
the BRI standard for construing unexpired patent claims and proposed claims
in IPR, PGR, and CBM proceedings with an approach that follows the
framework set forth in Phillips.”). Post-issuance procedures include litigation
involving infringement and validity before courts and inter partes review (IPR),
post-grant review (PGR) and covered business method review (CBM)
proceedings before the PTAB. See MPEP § 2111 (9th ed. Rev. 10.2019, June
2020). Inter partes review is a “trial proceeding conducted at the [PTAB] to
review the patentability of one or more claims in a patent only on a ground that
could be raised under [35 U.S.C.] §§ 102 or 103, and only on the basis of prior
art consisting of patents or printed publications.” Inter Partes Disputes, USPTO
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claim a broader scope than the Phillips standard,69 “there have
been very few decisions in which courts have attributed a
variance in claim interpretation to the differences between the
two standards.”70
Consider a hypothetical claim to obtain a tangible sense of
claim scope: A drug for a disease X, consisting of a main
structure M, and an element attached to M, wherein the element
is A, B, or C. Accordingly, this hypothetical claim covers at most
three compounds, i.e., M-A, M-B, and M-C combinations. If the
preamble “for disease X” is construed as a limitation,71 the claim
then covers only the ones that are effective for treating disease
X among the three possible combinations. The specification is

(Apr. 2, 2013, 02:39 PM EDT), https://www.uspto.gov/patents/laws/americainvents-act-aia/inter-partes-disputes#heading-1. See 37 C.F.R. §§ 42.100–.123
(2012) for detailed rules governing inter partes review. Post grant review is a
“trial proceeding conducted at the [PTAB] to review the patentability of one or
more claims in a patent on any ground that could be raised under [35 U.S.C.] §
282(b)(2) or (3).” Inter Partes Disputes, supra. See 37 C.F.R. §§ 42.200–.224
(2012) for detailed rules governing post grant review. The covered business
method review, repealed on September 15, 2020, is a “trial proceeding
conducted at the [PTAB] to review the patentability of one or more claims in a
covered business method patent.” Inter Partes Disputes, supra. See 37 C.F.R. §§
42.300–.304 (2012) for detailed rules governing covered business method
review.
69. Facebook, Inc. v. Pragmatus AV, LLC, 582 F. App’x 864, 869 (Fed. Cir.
2014) (“The broadest reasonable interpretation of a claim term may be the same
as or broader than the construction of a term under the Phillips standard. But
it cannot be narrower.”).
70. KEVIN GREENLEAF ET AL., INTELL. PROP. OWNERS ASS’N, HOW
DIFFERENT ARE THE BROADEST REASONABLE INTERPRETATION AND PHILLIPS
CLAIM CONSTRUCTION STANDARDS? 1 (2018).
71. Whether a preamble limits a claim is determined on a case-by-case
basis. See, e.g., Applied Materials, Inc. v. Advanced Semiconductor Materials
Am., Inc., 98 F.3d 1563, 1572–73 (Fed. Cir. 1996) (“Whether a preamble stating
the purpose and context of the invention constitutes a limitation of the claimed
process is determined on the facts of each case in light of the overall form of the
claim, and the invention as described in the specification and illuminated in the
prosecution history.”). It is a settled rule that “a preamble generally is not
limiting where a patentee defines a structurally complete invention in the claim
body and uses the preamble only to state a purpose or intended use for the
invention.” Catalina Mktg. Int’l, Inc. v. Coolsavings.com, Inc., 289 F.3d 801, 808
(Fed. Cir. 2002) (quotation marks omitted). Nevertheless, courts have
considered claims similar to the hypothetical claim and acknowledged the
preambles were limiting. E.g., Idenix Pharms. LLC v. Gilead Scis., Inc., 941
F.3d 1149, 1155–56 (Fed. Cir. 2019) (interpreting the preamble “[a] method for
the treatment of a hepatitis C virus infection” as a narrowing functional
limitation because the district court constructed the claim as such and neither
party challenged this construction).
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then required to provide enough guidance on how to make and
use these compounds, including how to synthesize them and
determine their efficacy, unless such guidance can be found in
the prior art or is within the common knowledge of a
PHOSITA.72 In addition, the necessary experimentation, which
is synthesizing and testing the compounds in this example, may
not be considered undue experimentation.73
Obviously, the more species a claim covers, the more
guidance the patentee needs to provide for enablement purposes.
The scope of a claim decides how big the set of combinations
needs to be enabled, while other factors decide whether the set
of combinations is enabled.
b. Level of PHOSITA and State of Art
A PHOSITA74 is a “hypothetical person who is presumed to
be aware of all the pertinent prior art.”75 Section 112(a) requires
that the patent document enable “any person skilled in the art to
which it pertains” to practice the full scope of the claim.76
Accordingly, the level of a PHOSITA is fundamental in deciding
whether a claim is enabled. Factors for determining the level of
PHOSITA include: the “type of problems encountered in art;
prior art solutions to those problems; rapidity with which
innovations are made; sophistication of the technology; and
educational level of active workers in the field.”77 For a given
case, it is possible that not all the listed factors are present, and
“one or more of them may predominate.”78
The state of an art is related to how much a PHOSITA
knows about the art. When the art is fairly new, a PHOSITA is
considered to have “little or no knowledge independent from the
patentee’s instruction”79 and thus the patentee must provide

72. See infra Section I.A.1.b.
73. See infra Section I.A.1.d.
74. Other expressions for the same concept include a person skilled in the
art (PSITA), a person of ordinary skills in the art (POSITA), and those skilled
in the art.
75. Custom Accessories, Inc. v. Jeffrey-Allan Indus., Inc., 807 F.2d 955, 962
(Fed. Cir. 1986) (citation omitted).
76. 35 U.S.C. § 112(a) (emphasis added).
77. Custom Accessories, 807 F.2d at 962.
78. Id. at 963.
79. Chiron Corp. v. Genentech, Inc., 363 F.3d 1247, 1254 (Fed. Cir. 2004).
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“specific and useful teaching.”80 In contrast, if the art is mature
and a PHOSITA knows how to perform necessary
experimentation, then such teaching is not needed and
preferably omitted from the specification.81
c. Predictability and Nature of Art
Related to, but distinctive from, the state of an art,
predictability is about how much can be anticipated from what
is known of the art. As explained by the PTO, “[i]f one skilled in
the art can readily anticipate the effect of a change within the
subject matter to which the claimed invention pertains, then
there is predictability in the art.”82 A PHOSITA’s understanding
of an art affects how much can be anticipated from available
information. Therefore, the state of an art and the skill level of
a PHOSITA provide evidence as to the question of
predictability.83
Predictability is also closely related to the nature of an art.
At one end of the predictability spectrum, a sophisticated
mechanical engineer can design a mechanical device and know
it will work without actually building it; at the other end, many
drugs were discovered by serendipity and chance observations,84
and pharmaceutical experts can hardly predict what variations
can be made to achieve a better effect.85 Based on such drastic
80. Genentech, Inc. v. Novo Nordisk, A/S, 108 F.3d 1361, 1368 (Fed. Cir.
1997).
81. Spectra-Physics, Inc. v. Coherent, Inc., 827 F.2d 1524, 1534 (Fed. Cir.
1987) (“A patent need not teach, and preferably omits, what is well known in
the art.”).
82. MPEP § 2164.03 (9th ed. Rev. 10.2019, June 2020).
83. Id.
84. See Pushkar N. Kaul, Drug Discovery: Past, Present and Future, in
PROGRESS IN DRUG RESEARCH 9, 15–16 (Ernst Jucker ed., 1998) (“[T]he overall
chronology of new drug discoveries of significance in the 20th century weighs
heavily in favor of serendipity and chance observations. A few examples
are . . . [c]hlorpromazine, . . . [f]urosemide (Lasix), . . . [and] [c]yclosporine . . .
.”); see, e.g., SUSAN ALDRIDGE & JEFFREY L. STURCHIO, AM. CHEM. SOC’Y & THE
ROYAL SOC’Y OF CHEMISTRY, THE DISCOVERY AND DEVELOPMENT OF
PENICILLIN 1928–1945, at 3 (1999) (detailing how the discovery of penicillin
began with serendipity).
85. See Kaul, supra note 84, at 10 (“New drug discovery from early on
involved a trial-and-error approach on naturally derived materials and
substances until the end of the nineteenth century.”); see, e.g., Idenix Pharms.
LLC v. Gilead Scis. Inc., 941 F.3d 1149, 1155 (Fed. Cir. 2019) (“[I]n the
nucleoside area[, a specific type of chemicals,] . . . the smallest change can have
a dramatic effect not only on the activity of that compound but on the toxicity
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differences in predictability, courts generally treat mechanical
and electrical engineering as predictable arts, and chemistry
and biology as unpredictable arts.86
Predictability is of critical importance when determining
whether a claim satisfies the enablement requirement. As stated
above, the Fisher court has established a “quantitative”
relationship between the degree of predictability and the
enablement effect: “[T]he scope of enablement . . . varies
inversely with the degree of unpredictability of the factors
involved.”87 Predictability also makes a “qualitative” difference
for the question of whether a genus claim can be enabled by one
single embodiment: “In mechanical cases, . . . broad claims may
be supported by a single form of the apparatus disclosed in an
applicant’s application,”88 but “in chemical cases, where an
applicant [disclosed only one material], he is not entitled to
broader claims than for the material originally disclosed.”89
d. Quantity and Routineness of Experimentation
According to the Wands court, while a large quantity of
necessary experimentation does tip the scale towards the undue
experimentation side, it may be defeated “if [the
experimentation] is merely routine, or if the specification in
question provides a reasonable amount of guidance with respect
to the direction in which the experimentation should proceed.”90
When determining the routineness of experimentation, courts
usually consider time and difficulty of the experimentation,
success and failure of past attempts, and the skill level of a
PHOSITA.91

of the compound. So nothing is predictable.” (quotation mark omitted) (citation
omitted)).
86. In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970).
87. Id. (emphasis added).
88. In re Vickers, 141 F.2d 522, 526–27 (C.C.P.A. 1944).
89. In re Soll, 97 F.2d 623, 624 (C.C.P.A. 1938); see also MPEP § 2164.03
(9th ed. Rev. 10.2019, June 2020) (“A single embodiment may provide broad
enablement in cases involving predictable factors, such as mechanical or
electrical elements. However, in applications directed to inventions in arts
where the results are unpredictable, the disclosure of a single species usually
does not provide an adequate basis to support generic claims.” (citations
omitted)).
90. In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
91. See, e.g., ALZA Corp. v. Andrx Pharms., LLC, 603 F.3d 935, 941–43
(Fed. Cir. 2010).
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Nevertheless, about a decade after the Wands decision, the
Federal Circuit further added that routine experimentation
must also be of a reasonable amount.92 Nowadays, courts have
repeatedly determined claims that require large quantities of
routine experimentations to be non-enabled.93
e. Guidance and Examples
As discussed above, the necessary amount of guidance
depends on the scope of claim, the state of art, the skill level of a
PHOSITA, the nature of art, and predictability.94 Guidance may
be in the form of general principles, but it is more often provided
by specific examples of how the invention is practiced. “An
example may be ‘working’ or ‘prophetic,’” where the former “is
based on work actually performed,” and the latter is “based on
predicted
results.”95
Of
note,
“[u]se
of
prophetic
examples . . . does not automatically make a patent nonenabling.”96 When the prophetic examples are reasonably
reliable, they can also contribute to enablement.97

92. Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 1371 (Fed. Cir.
1999) (“We have held that a patent specification complies with the statute even
if a ‘reasonable’ amount of routine experimentation is required in order to
practice a claimed invention, but that such experimentation must not be
‘undue.’” (citation omitted)); Wyeth & Cordis Corp. v. Abbott Lab’ys, 720 F.3d
1380, 1386 (Fed. Cir. 2013) (“[R]outine experimentation is ‘not without bounds.’”
(citation omitted)).
93. See Wyeth, 720 F.3d at 1385 (holding that “having to synthesize and
screen each of at least tens of thousands of candidate compounds constitutes
undue experimentation,” even though “one of ordinary skill could routinely use
the assays disclosed in the specification to determine immunosuppressive and
antirestenotic effects in candidate compounds”); see also Idenix Pharms. LLC v.
Gilead Scis. Inc., 941 F.3d 1149, 1162 (Fed. Cir. 2019) (“Weighing each of these
factors, we conclude as a matter of law that the [patent at issue] is invalid for
lack of enablement. As described above, a reasonable jury could only have found
that at least many, many thousands of [species] meet the structural limitations
of [the claim at issue], not all of which [meet the functional limitation].”).
94. See supra Sections I.A.1.a–c.
95. MPEP § 2164.02 (9th ed. Rev. 10.2019, June 2020).
96. Atlas Powder Co. v. E.I. du Pont de Nemours & Co., 750 F.2d 1569, 1577
(Fed. Cir. 1984).
97. Id. (“[T]he ‘prophetic’ examples of the specification were based on actual
experiments that were slightly modified in the patent to reflect what the
inventor believed to be optimum, and hence, they would be helpful in enabling
someone to make the invention.”).

2022]

PATENTING THE "UNPREDICTABLE"

687

2. Relationship with Utility Requirement
A claim may also fail the enablement requirement as a
result of failing the utility requirement under 35 U.S.C. § 101.98
The logic is straightforward: “[I]f a claimed invention does not
have utility, the specification cannot enable one to use it.” 99
The utility requirement is usually a low bar.100 An invention
has a utility if: (1) a specific and substantial use is apparent or
identified by the patentee; and (2) the invention is operative.101
A utility is specific if the utility is “particular to the subject
matter claimed”102 and “can be used to provide a well-defined
and particular benefit to the public.”103 For example, in In re
Fisher, a claim reciting “expressed sequence tags” (ESTs) for
encoding certain maize protein fragments was found not to have
specific utility because all the seven utilities identified by the
applicants were related to general ESTs and not specific to the
ESTs claimed. 104 As another example, in In re Kirk, the claimed
compounds were said to have a “biological activity,” but the exact
biological activity was not specified.105 Such use was also
rejected as not specific.106
A claim has a substantial utility only if the “claimed
invention has a significant and presently available benefit to the
public.”107 For example, a process for producing a compound of
no known use is not of a substantial utility. 108 As the court

98. “Whoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor . . . .” 35 U.S.C. § 101 (emphasis added).
99. In re Brana, 51 F.3d 1560, 1564 (Fed. Cir. 1995).
100. See Brooktree Corp. v. Advanced Micro Devices, Inc., 977 F.2d 1555,
1571 (Fed. Cir. 1992) (“To violate [35 U.S.C.] § 101 the claimed device must be
totally incapable of achieving a useful result.”); see also E.I. du Pont de Nemours
& Co. v. Berkley & Co., 620 F.2d 1247, 1260 n.17 (8th Cir. 1980) (“A small degree
of utility is sufficient. The claimed invention must only be capable of performing
some beneficial function.”(citation omitted)).
101. E.I. du Pont de Nemours, 620 F.2d at 1260 n.17.
102. In re Fisher, 421 F.3d 1365, 1372 (Fed. Cir. 2005) (citing MPEP
§ 2107.01).
103. Id. at 1371.
104. Id. at 1368, 1373.
105. In re Kirk, 376 F.2d 936, 938 (C.C.P.A. 1967).
106. Id. at 941.
107. Fisher, 421 F.3d at 1371.
108. See Brenner v. Manson, 383 U.S. 519, 532–36 (1966) (holding that a
process for making a steroid of no known use did not satisfy the utility
requirement).
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recognized, the compound might be found of significant use in
the future,109 but a substantial utility requires a “presently
available benefit.”110 Of particular relevance to this Note,
regarding an invention for treating pathological conditions in a
human body, its therapeutic effects shown in in vitro and/or
animal testing are sufficient to support a substantial utility if
“there exists a satisfactory correlation” between the in vitro
and/or animal testing results and the effects observed in
humans.111
Lastly, an invention is operative if it works for its intended
use.112 The mere existence of inoperative embodiments within
the scope of a claim does not necessarily result in the claim
failing the utility requirement or being non-enabled.113 The
standard is whether a PHOSITA, in view of the specification, can
clearly identify the operative embodiments that fall within the
claim scope without undue experimentation.114

109. Id. at 535–36 (“This is not to say that we mean to disparage the
importance of contributions to the fund of scientific information short of the
invention of something ‘useful,’ or that we are blind to the prospect that what
now seems without ‘use’ may tomorrow command the grateful attention of the
public.”).
110. Fisher, 421 F.3d at 1371.
111. Rey-Bellet v. Engelhardt, 493 F.2d 1380, 1384 (C.C.P.A. 1974); see also
Ex parte Maas, No. 86-0178, 1987 WL 123900, at *3 (B.P.A.I. May 19, 1987); Ex
parte Balzarini, No. 91-0958, 1991 WL 332576 (B.P.A.I. Mar. 21, 1991).
112. See E.I. du Pont de Nemours & Co. v. Berkley & Co., 620 F.2d 1247,
1260 n.17 (8th Cir. 1980) (“An invention does not lack utility merely because
the particular embodiment disclosed in the patent lacks perfection or performs
crudely. A commercially successful product is not required. Nor is it essential
that the invention accomplish all its intended functions or operate under all
conditions, partial success being sufficient to demonstrate patentable utility. In
short, the defense of non-utility cannot be sustained without proof of total
incapacity.” (citations omitted)).
113. Atlas Powder Co. v. E.I. du Pont de Nemours & Co., 750 F.2d 1569, 1576
(Fed. Cir. 1984) (“Even if some of the claimed combinations were inoperative,
the claims are not necessarily invalid.”).
114. See MPEP § 2164.08(b) (9th ed. Rev. 10.2019, June 2020) (“However,
claims reading on significant numbers of inoperative embodiments would
render claims non-enabled when the specification does not clearly identify the
operative embodiments and undue experimentation is involved in determining
those that are operative.” (citing Atlas Powder, 750 F.2d at 1577)).
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B. WRITTEN DESCRIPTION REQUIREMENT
The written description requirement under 35 U.S.C. § 112
has “significant overlap” with the enablement requirement,115
yet they are “separate and distinct.” 116 The written description
requirement serves two policy goals: (1) convey to the public
what the patentee claims as the invention; and (2) “demonstrate
that the patentee was in possession of the invention that is
claimed.”117 Practically, both the enablement and written
description requirements police patent claims from
overreaching: The enablement requirement makes sure that a
patentee is not able to claim more than she has enabled the
public to practice, and the written description requirement
guarantees that a patentee does not exclude more than she has
actually invented.118 To demonstrate this point, consider the
facts in Schriber-Schroth119 as an example. The patentee
claimed a piston comprising a web, and the claim did not recite
any limitation regarding the rigidity of the web.120 The
specification, however, described only pistons comprising
“extremely rigid” webs.121 The change of rigidity of the web
component might necessitate changes of the other components
of the piston or even the overall structure.122 Responding to the

115. Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 921 (Fed. Cir.
2004).
116. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1344 (Fed. Cir.
2010) (“We . . . hold that § 112, first paragraph, contains two separate
description requirements: a ‘written description [i] of the invention, and [ii] of
the manner and process of making and using [the invention’].” (alteration in
original) (citation omitted)).
117. Capon v. Eshhar, 418 F.3d 1349, 1357 (Fed. Cir. 2005).
118. See MPEP §§ 2163.I, 2164 (9th ed. Rev. 10.2019, June 2020). The
written description requirement also polices claims filed with improper timing,
which is not the focus of this Section and thus briefly explained in this footnote.
During the patent application process, the applicant may amend the
application, including adding new features to claims. When the amended claims
are not supported by the original filed specification, the claims fail the written
description requirement. Similarly, when the applicant files a continuation
application, the original specification might also fail to support the newly filed
claims. See MPEP § 2163.I (9th ed. Rev. 10.2019, June 2020) for a
comprehensive introduction of failing the written description requirement due
to improper timing.
119. Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47 (1938).
120. Id. at 54–55.
121. Id. at 55.
122. Id. at 59 (“Inherent flexibility of the web . . . cannot be depended upon
to produce the desired effect . . . . As [patentee’s] own expert testified, that
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patentee’s argument that a PHOSITA would be able to adapt the
piston with a flexible web, the United States Supreme Court
stated, “[e]ven if those skilled in the art would have known [how
to make such adaptions], that was not the invention which [the
patentee] described by his references to an extremely rigid
web.”123
Nevertheless, courts have also acknowledged that “there is
little difference in some fields between describing an invention
and enabling one to make and use it,” but that is rarely the case
for inventions in unpredictable arts.124 Indeed, it is a repeated
theme in chemical and biological patents that the genus claim
may have been enabled, but it is nevertheless insufficiently
described.125
When evaluating the adequacy of the description for a genus
claim, courts consider factors similar to the Wands factors,
namely, “the existing knowledge in the particular field, the
extent and content of the prior art, the maturity of the science or
technology, [and] the predictability of the aspect at issue.”126
Ultimately, the test is whether the description allows a
PHOSITA to “visualize or recognize the members of the
genus.”127 Any form of description is allowed as long as this test
is passed, including providing “a precise definition, such as by
structure, formula, chemical name, physical properties, or other
properties[] of . . . the genus,”128 claiming by function129 if “the
art has established a correlation between structure and

depends upon design of the web, with correct proportioning of the different parts
as to location and thickness to produce lateral flexibility.”).
123. Id. at 58–59.
124. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1352 (Fed. Cir.
2010).
125. In re DiLeone, 436 F.2d 1404, 1405 (C.C.P.A. 1971) (“[I]t is possible for
a specification to enable the practice of an invention as broadly as it is claimed,
and still not describe that invention.”); see, e.g., Ex parte Kubin, No. 2007-0819,
2007 WL 2070495 (B.P.A.I. May 31, 2007) (reversing the enablement rejection
but affirming the written description rejection).
126. Capon v. Eshhar, 418 F.3d 1349, 1359 (Fed. Cir. 2005).
127. Eli Lilly, 598 F.3d at 1350 (quotation marks omitted).
128. Id.
129. Claiming by function, in contrast to claiming by structure, is to claim
an invention “by what it does rather than by what it is.” In re Swinehart, 439
F.2d 210, 212 (C.C.P.A. 1971). For example, if the preamble “a drug for disease
X” of the hypothetical claim in supra Section I.A.1.a, then this preamble is a
functional limitation, and the claim covers only the species that show some
effectiveness to disease X.
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function,”130 and listing “a representative number of species
falling within the scope of the genus or structural features
common to the members of the genus.”131
1. Description by Listing “a Representative Number of
Species”132
Describing a claim by listing “a representative number of
species”133 is most often used when the structure and function
relationship is not completely understood. It has also invited a
myriad of written description-related litigation. 134 Courts have
refused to specify how many species constitute a representative
number because “this number necessarily changes with each
invention.”135 Nevertheless, as illustrated below, both logic and
relevant cases support the proposition that in order to list “a
representative number of species,”136 the key resides in the
representativeness of the listed species rather than the number
itself.
Logically, to allow a PHOSITA to visualize the members of
a genus by describing a representative number of species, the
described species should bear a considerable similarity to
undescribed species and be sufficiently diverse so as to represent
a substantial portion of different species.137 For example,
consider a hypothetical scenario where one-hundred compounds
are covered by a claim. Among the one-hundred compounds, ten
compounds comprise main structure M1, and ninety comprise
main structure M2. A description of all ten compounds of main
structure M1 is not a sufficient description of the claim because
the described compounds cannot represent the ones of main
structure M2. In contrast, a description of one compound of main
structure M1 and one of M2 may be a sufficient disclosure for

130. Eli Lilly, 598 F.3d at 1350.
131. Id.
132. Id.
133. Id.
134. See, e.g., Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559
(Fed. Cir. 1997); Invitrogen Corp. v. Clontech Lab’ys, Inc., 429 F.3d 1052 (Fed.
Cir. 2005); Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330 (Fed.
Cir. 2021).
135. Eli Lilly, 598 F.3d at 1351.
136. Id. at 1350.
137. This logical inference is inspired by the standard for representativeness
of data in AI development. See infra note 163 and accompanying text.
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the claim if the described ones can each represent the other
compounds of their kinds.
Cases before the PTO and courts are consistent with this
logical inference. For example, in Ex parte Kubin, the challenged
claim was directed to “a genus of polynucleotides encoding
polypeptides at least 80% identical to amino acids 22-221 of SEQ
ID NO:2 which bind to CD48.”138 The applicant listed five
sequences that fell within the scope of this claim. 139 However,
observing that “[n]one of these sequences varies amino acids 22221,” the Board held the listed sequences were “not
representative of the genus.”140 In other words, the described
species were not sufficiently diverse because they failed to
represent the species that are less than 100% identical to amino
acids 22-221, which account for a portion—perhaps a major
portion—of the whole claimed genus. Another example is
Invitrogen Corp. v. Clontech Laboratories, Inc., where the claim
at issue recited, “[a]n isolated polypeptide . . . encoded by a
modified reverse transcriptase [‘RT’] nucleotide sequence . . . ,
wherein said nucleotide sequence is derived from . . . a
retrovirus, yeast, Neurospora, Drosophila, primates [or]
rodents.”141 In the specification, the patentee described two
nucleotide sequences (also known as DNA or genes) and referred
to eight publications for providing the nucleotide sequences
derived from five different retroviruses, three different yeasts,
and some primates and rodents.142 Moreover, the court found
that “members of the RT gene family shared significant
homologies from one species of RT to another.”143 Accordingly, in
this case, the species were similar to some of the others, and the
described species were diverse enough to cover each type of
claimed species. Although the court did not explicitly provide
this line of reasoning, it held the patent satisfied the written
description requirement after stating the cited facts. 144
138. Ex parte Kubin, No. 2007-0819, 2007 WL 2070495, at *9 (B.P.A.I. May
31, 2007) (quotation marks omitted).
139. Id. (“In this case, Appellants have sequenced two nucleic acids falling
within the scope of claim 73 and three fusion proteins whose nucleotide
sequences would fall within the scope of claim 73.”).
140. Id.
141. Invitrogen Corp. v. Clontech Lab’ys, Inc., 429 F.3d 1052, 1072 (Fed. Cir.
2005) (citing U.S. Patent No. 6,063,608, col. 19 ll. 26–34 (filed Feb. 10, 1997)).
142. U.S. Patent. No. 6,063,608 col. 9 ll. 34–47 (filed Feb. 10, 1997).
143. Invitrogen, 429 F.3d at 1073.
144. Id. at 1073–74.
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Of course, if the number of listed species is too small, the
listed species will not be diverse enough to represent the claimed
genus, which is what happened in Ariad v. Eli Lilly (no concrete
examples presented), 145 UC v. Eli Lilly (describing rat insulin
cDNA only while claiming genus of vertebrate and mammalian
insulin cDNA),146 and Juno v. Kite (describing two examples of
binding elements that bind to two targets, respectively, but
claiming binding elements without limiting the targets).147
A representativeness issue may also arise when too many
listed examples are not within the scope of the genus claim such
that a PHOSITA cannot “visualize or recognize the members of
the genus.”148 After all, an example that is not a species of a
claimed genus cannot represent those that are. Therefore,
providing a “laundry list” of all possible species will not help
satisfy the written description requirement.149 A stronger caveat
to the “laundry list” practice is that if the accused species is not
included in the list, it will be extremely difficult for the patentee
to convince a jury that she is in possession of this species. 150
II. AI’S POWER IN PREDICTING “UNPREDICTABLE” ARTS
While genus claims in the unpredictable arts are having a
hard time meeting the enablement and written description

145. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1357–58 (Fed. Cir.
2010) (“The . . . patent discloses no working or even prophetic examples of [the
claimed method] . . . .”).
146. Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1568 (Fed.
Cir. 1997) (“[A] description of rat insulin cDNA is not a description of the broad
classes of vertebrate or mammalian insulin cDNA.”).
147. Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330, 1337 (Fed.
Cir. 2021) (“The disclosure of one scFv [i.e., single-chain antibody variable
fragment, a type of binding element,] that binds to CD19 and one scFv that
binds to a PSMA antigen on prostate cancer cells in the manner provided in this
patent does not provide information sufficient to establish that a skilled artisan
would understand how to identify the species of scFvs capable of binding to the
limitless number of targets as the claims require.”).
148. Eli Lilly, 598 F.3d at 1350 (quotation marks omitted).
149. See Fujikawa v. Wattanasin, 93 F.3d 1559, 1571 (Fed. Cir. 1996)
(“[S]imply describing a large genus of compounds is not sufficient to satisfy the
written description requirement as to particular species or sub-genuses.”).
150. See, e.g., Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149, 1164
(Fed. Cir. 2019) (“The specification . . . provides no method of distinguishing
effective from ineffective compounds for the compounds reaching beyond the
formulas disclosed in the . . . patent . . . . In the absence of that guidance, the
listed examples and formulas cannot provide adequate written description
support for undisclosed nucleosides that also happens to [be effective].”).
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requirements,151 AI techniques have progressed to the point
where they are capable of making reasonably accurate
predictions for many important problems in these
“unpredictable” arts. 152 To properly translate AI’s prediction
power into a new patent practice, it is necessary to understand
how AI works, how well it works, and its limitations. Before
proceeding to these topics, it is worth clarifying that machine
learning (ML) is a major portion of currently available AI.153
Similar to other articles related to AI and ML, hereinafter, this
Note uses ML and AI interchangeably.154

151. See supra Part I.
152. For the sake of completeness, a pure computation approach based on
established scientific principles can also provide predictions in the traditionally
unpredictable arts. See Keith T. Butler et al., Machine Learning for Molecular
and Materials Science, 559 NATURE 547, 547 (2018) (“The field of computational
chemistry has become increasingly predictive in the twenty-first century, with
activity in applications as wide ranging as catalyst development for greenhouse
gas conversion, materials discovery for energy harvesting and storage, and
computer-assisted drug design.” (citation omitted)). Although the pure
computation approach remains an option for assisting research and
development in many industries, AI is more advantageous because: (1) AI
requires fewer computational resources, see Angeles Pulido et al., Functional
Materials Discovery Using Energy-Structure-Function Maps, 543 NATURE 657,
657 (2017) (“Computational prediction of stability and function has great
potential . . . but it is difficult in practice because of the computational
expense . . . .”); and (2) AI can better handle non-ideal and complex situations,
see Marwin H. S. Segler & Mark P. Waller, Neural-Symbolic Machine Learning
for Retrosynthesis and Reaction Prediction, 23 CHEM. EUR. J. 5966, 5966 (2017)
(discussing how the rule-based approach of pure computation “cannot predict
anything outside of their knowledge”). Nevertheless, in a scenario where the
pure computation approach can make satisfactory predictions, arguments
regarding AI application in patent practice in infra Part III are generally
applicable to the pure computation approach as well.
153. See ETHEM ALPAYDIN, INTRODUCTION TO MACHINE LEARNING 3 (2d ed.
2010) (explaining what machine learning is and providing examples of it).
154. See, e.g., Xin Yang et al., Concepts of Artificial Intelligence for
Computer-Assisted Drug Discovery, 119 CHEM. REV. 10520, 10521 (2019) (“[W]e
will use the term ‘AI’ as a synonym for certain machine learning techniques
. . . .”); Lucas B. Ayres et al., Taking the Leap Between Analytical Chemistry and
Artificial Intelligence: A Tutorial Review, 1161 ANALYTICA CHIMICA ACTA, no.
338403, 2021, at 3 (“[M]ost of the papers discussed in this review do not make
an explicit difference between AI and machine learning . . . .”).
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A. AI WORK PRINCIPLES
The basic AI workflow155 can be briefly summarized as data
preparation, model training, and model evaluation and
optimization. 156
1. Data Preparation
Data preparation is a non-trivial step in any AI training
processes because “it underpins all further progress.” 157 AI
performance heavily depends on “the representativeness,
quality, and quantity of initial data.”158
As the old saying goes, “garbage in, garbage out.”159 Data
quality is critically important for AI development.
Unfortunately, “[t]here is no universal approach to verifying the
quality of . . . data.”160 “One needs to understand the origin and
meaning of the training data” to eliminate incomplete,

155. For the reasons below, the AI workflow introduced in this Section is for
supervised learning only. Current learning modes can be generally categorized
as supervised learning or unsupervised learning. Yang et al., supra note 154, at
10525. In supervised learning, the training data includes input values and
corresponding output values. Butler et al., supra note 152, at 548. The goal of
supervised learning is “to derive a function that, given a specific set of input
values, predicts the output values to an acceptable degree of fidelity.” Id. In
unsupervised learning, the training data includes input values only. Yang et
al., supra note 154, at 10525. The aim of unsupervised learning is “to find the
regularities in the input,” ALPAYDIN, supra note 153, at 11, such as “trends,
patterns or clustering in the data.” Butler et al., supra note 152, at 548. Since
supervised learning is mostly used when predictions are desired, see Yang et
al., supra note 154, at 10525 (“Many AI learning algorithms use a supervised
learning process, . . . and the goal of the training process is to learn a mapping
function from the input to the output . . . such that the class labels Y (in case of
a classifier) or target values Y (for quantitative output data) for unseen data X
can be correctly predicted.” (citation omitted)), this Section introduces the
workflow for supervised learning only.
156. See ALTUNA AKALIN, COMPUTATIONAL GENOMICS WITH R § 5.2 (2020),
https://compgenomr.github.io/book/ (providing an overview of the steps used in
supervised learning).
157. Yang et al., supra note 154, at 10536.
158. Id.
159. “In computer science, garbage in, garbage out (GIGO) is the concept
that flawed, or nonsense (garbage) input data produces nonsense output.”
Garbage in, Garbage out, WIKIPEDIA, https://en.wikipedia.org/wiki/Garbage_in
,_garbage_out (last updated June 9, 2022) (emphasis omitted).
160. DAVID J. L ILJA, LINEAR REGRESSION USING R: AN INTRODUCTION TO
DATA MODELING 7 (1.1 ed. 2017).
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abnormal, and otherwise improper data entries to ensure a
reasonable data quality.161
The other two properties, representativeness and quantity
of data, are closely related but different. To ensure the
representativeness of data, one needs to confirm that the data
populates “the space of possible inputs that [users] might want
to make predictions for.”162 For example, if one desires to predict
the weather of Minnesota on a given day, a set of training data
that includes the weather of a whole past year possesses a better
representativeness than one that includes the weather in winter
of several past years. If the latter case happens, AI developers
will need to enlarge the quantity of data by accessing more
databases, repurposing data from other disciplines, or using
some innovative strategies to make the data populate the
“unpopulated” problem space.163
Additionally, closely related to this Note, data presentation
presents more difficulty in chemistry, biology, and materials
science than other disciplines due to their complexity.164
Consider the Minnesota weather example again. If one would
like to use Minnesota as a geographical input variable, “MN”
means nothing to a computer unless it is associated with its
longitude, latitude, and potentially the number of mountains
and lakes in it. Compounds need to be represented to a similar
effect as well.165 Nowadays, multiple representations for
compounds have been developed, including sequences, fixed-size

161. Yang et al., supra note 154, at 10536.
162. Id.
163. Databases and repurposing of data are discussed in infra Section II.C.
Examples of using innovative strategies to obtain more data include the works
of Raccuglia et al., see infra Section II.B.3.a, and Segler et al., see infra note 271.
164. For example, in computer vision, all pixels can be readily converted to
data that represents their corresponding colors. But structures of a molecule
cannot be easily transformed to numbers. See Yang et al., supra note 154, at
10536–37 for a detailed discussion of different methods for representing
molecules and their limitations.
165. The science community has established four requirements for
representations of compounds: (1) “Complete: Features of a material relevant to
the problem being studied should be captured;” (2) “Descriptive: Similar
materials should have similar representations;” (3) “Simple: Computing the
representation should be fast;” and (4) “Unique: All materials should have
exactly one representation.” Logan Ward & Chris Wolverton, Atomistic
Calculations and Materials Informatics: A Review, 21 CURRENT OP. SOLID
STATE & MATERIALS SCI. 167, 168 (2017).
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vectors, and molecular structure graphs.166 AI developers need
“insight into both the underlying scientific problem and the
operation of the learning algorithm” to choose the representation
that best serves their goals.167
In conclusion, the practice of AI developing “is said to consist
of at least 80% data processing and cleaning and 20% algorithm
application,”168 and “data preparation is a labor-intensive and
challenging task.”169
2. Model Training
Choosing a model is to assume how input and output data
are related.170 For example, if a model denoted as 𝑓𝜃 (∙) is chosen,
denoting input and output as 𝑥 and 𝑦, respectively, then it is
assumed that 𝑦 = 𝑓𝜃 (𝑥), where 𝜃 is a set of parameters of the
model 𝑓(∙).171 The training process is to feed the training data to
a computer, which comprises a set of 𝑥’s and corresponding 𝑦’s,
and then calculate 𝜃.172 After the computer finds an appropriate
parameter 𝜃, the exact relationship between 𝑥 and 𝑦, i.e., 𝑓𝜃 (∙),
is determined. 173 AI users can then use the trained model to
predict the output for new input. For instance, denoting a new
input as 𝑥′, then the prediction will be 𝑦 ′ = 𝑓𝜃 (𝑥′).174
Accordingly,
different
models
assume
different
relationships between inputs and outputs, and each has its

166. Yang et al., supra note 154, at 10536–37.
167. Butler et al., supra note 152, at 548.
168. Jessica Vamathevan et al., Applications of Machine Learning in Drug
Discovery and Development, 18 NATURE REVS. DRUG DISCOVERY 463, 466
(2019).
169. Yang et al., supra note 154, at 10536.
170. See ALPAYDIN, supra note 153, at 3–9 (illustrating machine learning
processes with examples).
171. To be more concrete, the exact relationship between 𝑥 and 𝑦 depends on
𝑓𝜃 (∙), which in turn depends on 𝜃. For example, suppose one chooses 𝑦 = 𝑓𝜃 (𝑥) =
𝑥 + 𝜃. Then if a computer finds 𝜃 = 1 according to the training data, the exact
relationship between 𝑥 and 𝑦 will be 𝑦 = 𝑓𝜃 (𝑥) = 𝑥 + 1. To make predictions, if
a new input 𝑥′ = 2 is given, the computer (now a trained AI) will predict the
corresponding output to be 𝑦′ = 2 + 1 = 3. Of course, no real AI models are this
simple. But the process of training AI and making predictions generally follows
this procedure.
172. See ALPAYDIN, supra note 153, at 41–42 (illustrating supervised
learning processes).
173. See id.
174. See id. at 5–11 (discussing how parameters are determined in
supervised learning processes).
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advantages and drawbacks.175 Moreover, training processes of
most models “are not fully autonomous, requiring at least some
guidance.”176 The values of parameters are often “estimated
beforehand using systematic and random searches, or
heuristics.”177 Accordingly, expertise and trial-and-error are
usually required in an AI training process. 178
3. Model Evaluation and Optimization
After an AI model is trained, one needs to evaluate and
usually optimize the trained model before using it for real
problems. 179 The key evaluation for AI is its performance on
unseen inputs.180 A widely used method for such evaluation is:
(1) randomly withholding a portion of data from being used in
the model training process; (2) using the trained model to predict
the outputs of the withheld data; and (3) comparing the
predicted outputs with the actual outputs. 181 The specific
comparison between predicted and actual output depends on
whether the AI is a classifier or regressor.182 Accordingly,

175. Antonio Lavecchia, Machine-Learning Approaches in Drug Discovery:
Methods and Applications, 20 DRUG DISCOVERY TODAY 318, 328 tbl. 2 (2015).
For example, advantages of the SVM model (used in the work of Raccuglia et
al., infra note 263) include: it “[d]oes not make any assumption about type of
relation between target property and molecular descriptors”; there is “low risk
of overfitting”; and it is “able to provide expected classification accuracies for
individual compounds.” Id. The SVM model’s disadvantages include that it is
used for “predominantly binary classification only.” Id. Advantages of the Naïve
Bayesian model (used in the work of Shi et al., infra note 236) include that it is
“not sensitive to irrelevant features;” and it “handles real and discrete data,”
and its disadvantages include that it “[a]ssumes independence of features.” Id.
176. Butler et al., supra note 152, at 549.
177. Id.
178. See id. (“Even modest changes in the values of hyperparameters can
improve or impair learning considerably, and the selection of optimal values is
often problematic.”).
179. Id.
180. Id.
181. Id. In addition, cross-validation is also a commonly used method for
evaluating AI performance. See ALPAYDIN, supra note 153, at 40.
182. See Butler et al., supra note 152, at 548. An AI is called a classifier if it
performs classification over data. In a classification scenario, the outputs 𝑦’s are
discrete values, such as “hot” or “cold” in the Minnesota weather example. In
contrast, in a regression scenario, the outputs 𝑦’s are continuous values, which
can be exact temperatures in the Minnesota weather example. See, e.g.,
ALPAYDIN, supra note 153, at 41 (“[The output] is 0/1 for two-class learning, is
a K-dimensional binary vector (where exactly one of the dimensions is 1 and all
others 0) for (K > 2)-class classification, and is a real value in regression.”).
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evaluation for classifiers and regressors are based on different
measures.
One of the most common performance measures for
classifiers is accuracy.183 Its definition is straightforward, that
is, the number of correct classification predictions divided by the
number of total predictions.184 It ranges from zero to one, where
one means the predictions are 100% accurate. Another popular
metric for classifiers is the area under the Receiver Operating
Characteristic (ROC)185 curve, known as the “AUC.”186 AUC has
become more widely used because it is arguably more
consistent187 and discriminating 188 than accuracy, the
aforementioned performance measure.189 The range of AUC is
183. E.g., Valentin Stanev et al., Machine Learning Modeling of
Superconducting Critical Temperature, 4 NPJ COMPUTATIONAL MATERIALS,
2018, at 1, 5 (using accuracy as one of the metrics evaluating a classifier).
184. Formally, accuracy is defined as
accuracy = (𝑡𝑝 + 𝑡𝑛)/(𝑡𝑝 + 𝑡𝑛 + 𝑓𝑝 + 𝑓𝑛)
where “tp” means true positive, “tn” true negative, “fp” false positive, and “fn”
false negative. Id. at 4.
185. “On an ROC graph, [true positive] is plotted on the Y axis and [false
positive] is plotted on the X axis. These statistics vary together as a threshold
on a classifier’s continuous output is varied between its extremes, and the
resulting curve is called the ROC curve.” Foster Provost & Tom Fawcett,
Analysis and Visualization of Classifier Performance: Comparison Under
Imprecise Class and Cost Distributions, in PROCEEDINGS OF THE THIRD
INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING
43, 44 (1997).
186. See ALPAYDIN, supra note 153, at 491 (“ROC allows a visual analysis; if
we want to reduce the curve to a single number we can do this by calculating
the area under the curve (AUC). A classifier ideally has an AUC of 1 and AUC
values of different classifiers can be compared to give us a general performance
averaged over different loss conditions.”).
187. Intuitively, if 𝑓 and 𝑔 are two different measures for evaluating two
learning algorithms A and B, 𝑓 and 𝑔 are said to be consistent if “𝑓 stipulates
that algorithm A is (strictly) better than B, then 𝑔 will not say B is better than
A.” Charles X. Ling et al., AUC: A Statistically Consistent and More
Discriminating Measure Than Accuracy, in PROCEEDINGS OF THE EIGHTEENTH
INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE 519, 521
(2003). See id. for a formal definition of degree of consistency.
188. Intuitively, if 𝑓 and 𝑔 are two different measures for evaluating two
learning algorithms A and B, 𝑓 is said to be more discriminating than 𝑔 if there
are cases where 𝑓 is able to reflect the difference between the performance of
algorithms A and B and 𝑔 is unable to provide such reflection, and not vice
versa. Id. See id. for formal definition of degree of discriminancy.
189. See generally id. But see Jorge M. Lobo et al., AUC: A Misleading
Measure of the Performance of Predictive Distribution Models, 17 GLOB.
ECOLOGY & BIOGEOGRAPHY 145 (2008) (questioning AUC’s “reliability as a
comparative measure of accuracy between model results”).

700

MINN. J.L. SCI. & TECH.

[Vol. 23:2

from zero to one, where one means the predictions are 100%
accurate, and 0.5 means a 50-50 guess.190
Performance measures for regressors are more complicated,
diverse, and controversial.191 Among them, Pearson’s correlation
coefficient (𝑟) or its square (𝑟 2 ), Mean Absolute Error (MAE) and
Mean Square Error (MSE) or its equivalent Root Mean Square
Error (RMSE) are most commonly used.192 MAE and RMSE both
reflect the average difference between the predicted and actual
values.193 The smaller the MAE and/or MSE/RMSE values, the
more accurate the regressor. Nevertheless, the values of MAE
and MSE/RMSE depend on the scale of data. 194 Therefore, one
can only use these two measures to evaluate AI for similar
problems but cannot obtain from them a general sense of how
good an AI’s performance is. Pearson’s correlation coefficient 𝑟
and 𝑟 2 are “statistical measure[s] of how well the model
describes the measured data.” 195 𝑟 and 𝑟 2 both range from zero
to one, and in general, the values that “are closer to one indicate
a better-fitting model.”196 Although 𝑟 and 𝑟 2 are measures of
correlation, they “have been used as predictive accuracy
measures in various disciplines in numerous studies . . . .”197
190. Alex J. Bowers & Xiaoliang Zhou, Receiver Operating Characteristic
(ROC) Area Under the Curve (AUC): A Diagnostic Measure for Evaluating the
Accuracy of Predictors of Education Outcomes, 24 J. EDUC. FOR STUDENTS
PLACED RISK 20, 22 (2019).
191. See Alexei Botchkarev, A New Typology Design of Performance Metrics
to Measure Errors in Machine Learning Regression Algorithms, 14 INTERDISC.
J. INFO., KNOWLEDGE, & MGMT. 45, 46 (2019) (summarizing more than forty
different metrics for regression models).
192. Jin Li, Assessing the Accuracy of Predictive Models for Numerical Data:
Not r nor r2, Why Not? Then What?, 12 PLoS ONE, no. 8, 2017, at 12 (“Of [the
measures for regressors], besides r and r2, MAE and root MSE (RMSE) are
among the most commonly used or recommended measures.” (citation omitted)).
193. Mathematically, MAE is given by
MAE = ∑_𝑖▒|𝑦_𝑖 − (𝑦_𝑖 ) ̂ | /𝑛
and RMSE is given by
RMSE = (∑_𝑖▒(𝑦_𝑖 − (𝑦_𝑖 ) ̂ )^2 /𝑛)^(1/2)
where 𝑦̂𝑖 is the predicted output value corresponding input 𝑥𝑖 , and 𝑦𝑖 is the
actual output value corresponding to 𝑥𝑖 . Botchkarev, supra note 191, at 61 tbl.
3 (displaying definitions of various metrics for regressors). Accordingly, the
absolute error of the i-th prediction is given by |𝑦𝑖 − 𝑦̂|,
𝑖 and the average and
squared average of errors are reflected by MAE and RMSE, respectively.
194. Li, supra note 192, at tbl. 2 (showing that MAE and MSE/RMSE are
not scale-independent).
195. LILJA, supra note 160, at 23.
196. Id. at 23–24.
197. Li, supra note 192, at 1–2.
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Since 𝑟 and 𝑟 2 are scale-independent, in contrast with MAE and
RMSE, this Note uses 𝑟 or 𝑟 2 as performance measures for
regressors in the next Section.
The AI developing process is not a one-time job.198 One
needs to evaluate and optimize the AI several times by adjusting
the parameters of the model, modifying the learning algorithm,
and/or improving the quantity and quality of training data until
the AI reaches satisfactory performance.199
B. AI APPLICATION IN DRUG DISCOVERY
The traditionally unpredictable arts, including chemistry
and biology, usually contribute “unpredictable factors”200 to
material and drug inventions.201 Although materials and drugs
are apples and oranges with respect to their technological
details, AI predictions in these two areas do not exhibit
qualitative differences. In short, AI is showing great
performance in predicting structures and properties for
materials202 and making considerable contribution to the
discovery of new materials. 203 Hundreds of AI-related papers in
198. See Yang et al., supra note 154, at 10537 fig. 14 (displaying a process
for developing and improving AI).
199. Id.
200. In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970).
201. E.g., U.S. Patent No. 10,161,021 (filed Apr. 20, 2017); U.S. Patent No.
7,608,597 (filed June 20, 2003).
202. E.g., Stanev et al., supra note 183, at 6 (presenting an AI that was able
to predict superconducting temperatures of known superconducting materials
with a correlation coefficient of 0.88, and some common features of materials
with high superconducting temperatures were extracted and more
superconducting materials were discovered based on the predictions); Jerome
G. P. Wicker & Richard I. Cooper, Will It Crystallise? Predicting Crystallinity of
Molecular Materials, 17 CRYSTENGCOMM 1927, 1930 (2015) (showing an AI
that achieved an accuracy of 90.3% in predicting whether sets of drug-like
compounds would crystallize, and conditions affecting the crystallization
tendency were found with the aid of AI); Rahman Sabouhi et al., Measuring the
Mechanical Properties of Polymer-Carbon Nanotube Composites by Artificial
Intelligence, 25 INT’L J. DAMAGE MECHS. 538, 553 (2016) (providing an AI that
was able to predict the depth-sensing indentation (DSI, an important
mechanical property for materials) of Polymer-Carbon nanotube composites
with a r2 score of 0.98, and claiming this AI would be a satisfying alternative to
conventional experiment measurement of DSI).
203. See, e.g., Pulido et al., supra note 152, at 657 (providing an energystructure-function map created by AI, several ultra-high-porous materials with
great gas adsorption potentials were identified including one that has been
experimentally confirmed to be the lowest density of any molecular organic
crystals known to date); Bryce Meredig et al., Combinatorial Screening for New
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materials science have been published every year since 2015,
and the number keeps growing fast.204 Accordingly, arguments
regarding AI applications in drug-related inventions are equally
applicable to material-related inventions.
Drug discovery is “the process of discovering new candidate
medications.”205 The research and development (R&D) of a new
drug has always been “a very expensive and time-consuming
process.”206 “[T]he cost of developing a new prescription medicine
that gains marketing approval is estimated to cost $2,558
million,” and the process “often lasts more than a decade.”207
Fortunately, the rational, computation-based (including AIbased) approach is more efficient than the traditional way of
drug discovery.208 Indeed, many AI-driven biopharmaceutical
companies, including Pharnext, Lantern Pharma, Healx, and
Innoplexus “have been committed to the development of drug
combinations based on [machine learning] and network
pharmacology methods.”209 The examples below account for just
a tiny portion of all available publications given the fact that
typically fifty to around one-hundred papers related to AI-

Materials in Unconstrained Composition Space with Machine Learning, 89
PHYSICAL REV. B, no. 9, 2014, at 094104-1, 094104-1, 094104-4 (providing AI
that was able to scan “millions to even trillions of candidate [ternary
compounds] in reasonable time” and predict their formation energies with an r2
score above 0.9, from which 4500 new stable ternary compounds were proposed);
Piyush M. Tagade et al., Attribute Driven Inverse Materials Design Using Deep
Learning Bayesian Framework, 5 NPJ COMPUTATIONAL MATERIALS, 2019, at 1
(presenting an approach of discovering materials from desired properties by AI,
which was claimed to be a general approach that can be used to find organic
semiconductors for thin-film transistors, small organic acceptors for solar cells
and electrolyte additives with high redox stability, and inorganic materials as
well).
204. Dane Morgan & Ryan Jacobs, Opportunities and Challenges for
Machine Learning in Materials Science, 50 ANN. REV. MATERIALS RSCH. 71, 73
fig. 1 (2020).
205. Natalie Stephenson et al., Survey of Machine Learning Techniques in
Drug Discovery, 20 CURRENT DRUG METABOLISM 185, 185 (2019).
206. Id.
207. Id.
208. Evanthia Lionta et al., Structure-Based Virtual Screening for Drug
Discovery: Principles, Applications and Recent Advances, 14 CURRENT TOPICS
MED. CHEMISTRY 1923, 1923 (2014).
209. Lianlian Wu et al., Machine Learning Methods, Databases and Tools
for Drug Combination Prediction, 23 BRIEFINGS BIOINFORMATICS, 2021, at 1,
16; see also Stephenson et al., supra note 205, at 188, 191 tbl. 2 (listing startup
companies that “are actively pioneering in the drug and medication discovery
and development field using AI techniques”).
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assisted drug discovery have been published every year since
2005. 210 Nevertheless, these examples show AI’s great power to
facilitate diverse aspects of R&D in the drug industry, and
particularly, with the aid of AI, the predictability of the
traditionally unpredictable arts is much higher than “drilling for
oil.”211
1. Virtual Screen and Property Prediction
The identification of lead compounds,212 i.e., promising drug
prospects that show pharmacological activity against a biological
target, is at the center of early-stage drug detection.213 This step
is conventionally performed by “experimental screening of large
libraries of chemicals against a therapeutically-relevant
target.”214 Thanks to the development of computation215 and AI
techniques, the screening can now be performed virtually (the
so-called “virtual screen”).216 In addition to predicting potency of
drug candidates, AI can also assist scientists to virtually screen
other drug properties, including absorption, 217 distribution,218

210. Stephenson et al., supra note 205, at 189 fig. (2).
211. Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 1372 (Fed. Cir.
1999) (noting that the district court analogized the predictability of antisense,
a specific biological mechanism, to “drilling for oil”).
212. A lead compound is “a drug-like small molecule . . . that will progress
into preclinical, and if successful, into clinical development and ultimately be a
marketed medicine.” J. P. Hughes et al., Principles of Early Drug Discovery, 162
BRIT. J. PHARMACOLOGY 1239, 1239 (2011) (citation omitted).
213. Lionta et al., supra note 208, at 1923.
214. Id.
215. See supra note 152 (introducing briefly the applications of computation
in the traditionally unpredictable arts).
216. Lionta et al., supra note 208; Yang et al., supra note 154, at 10538.
217. Drug absorption is the process by which “drug molecules are absorbed
into the bloodstream from the absorption site through one or more biological
membrane barriers.” Yang et al., supra note 154, at 10558.
218. “Distribution is the process by which drug molecules diffuse or are
actively transported from the bloodstream to body tissues, particularly the
tissue(s) where the action is expected to occur.” Id. at 10558–59.
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metabolism,219 excretion,220 and toxicity221 (collectively,
ADMET).222
Binding affinity.223 Usually, a drug’s effect begins when it
binds itself to a biomolecular target.224 Hence, binding affinity is
a good indication of a compound’s potential against certain
diseases. 225 Zilian & Sotriffer used experimentally confirmed

219. Metabolism, in this context, is the chemical transformation of drugs
inside the human body. Id. at 10559.
220. “Drug excretion is the process of removing drug molecules from the
body . . . .” Id. at 10561.
221. “Drug toxicity refers to the adverse effect on an organism or a
substructure of the organism (e.g., cells and organs) due to the action or
metabolism of a compound.” Id.
222. Id. at 10573.
223. “[B]inding affinity is the strength of the interaction between two (or
more than two) molecules that bind reversibly (interact).” Panagiotis L.
Kastritis & Alexandre M. J. J. Bonvin, On the Binding Affinity of
Macromolecular Interactions: Daring to Ask Why Proteins Interact, 10 J. ROYAL
SOC’Y INTERFACE, no. 79, 2013, at 6.
224. See TERRENCE P. KENAKIN, A PHARMACOLOGY PRIMER: THEORY,
APPLICATIONS, AND METHODS 2 (3d ed. 2009) (“[A]s a prerequisite to exerting
an effect, all drug molecules must bind to and interact with receptors.”).
225. Binding affinity is closely correlated to drug potency for “antagonists,”
but not for “agonists.” Id. at 81–82 (“There are . . . differences between binding
and functional experiments . . . . No differences should be seen for
antagonists . . . . The complex interplay between affinity and efficacy can be
misleading in structure activity studies for agonists.”). An “antagonist” is “a
pharmacologically active molecule that blocks physiological effect,” which
exerts no effects other than blocking the target site. Id. at 9. In contrast, an
“agonist” is “a molecule [that] binds to a receptor and produces its own
effect . . . .” Id. Accordingly, the drug potency of an antagonist only depends on
its binding affinity, while the drug potency of an agonist depends on both the
binding affinity and its efficacy. Efficacy is “[t]he property that gives a molecule
the ability to change a receptor, such that it produces a cellular response . . . .”
Id. at 14. Nevertheless, in either case, knowing the binding affinity of drug
candidates helps narrow the searching scope and is a good starting point for
virtual screening.
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binding affinity data sets226 to train a regression-based227
random forest (RF) model, 228 and achieved a Pearson’s
correlation coefficient229 up to 0.779 between the experimentally
measured and predicted binding affinity values.230 This is
significantly higher than the best predictions made by
traditional computation approaches, where the best correlation
coefficient is around 0.6.231
Pregnane X receptor232 activator. The activation of the
pregnane X receptor (PXR) by drugs may have a “substantial
impact on drug metabolism, transportation, and drug-drug
interactions.”233 Accordingly, knowing whether a drug candidate

226. Two types of datasets were used in the study: PDBbind and CSAR.
David Zilian & Christoph A. Sotriffer, SFCscoreRF: A Random Forest-Based
Scoring Function for Improved Affinity Prediction of Protein-Ligand Complexes,
53 J. CHEM. INFO. & MODELING 1923, 1924 (2013). Zilian & Sotriffer referred to
the PDBbind dataset as “generic” or “benchmark.” Id. The PDBbind dataset
includes binding affinity values of 1622 protein-ligand complexes, 900 of which
are particularly valuable for docking and scoring studies. Renxiao Wang et al.,
The PDBbind Database: Methodologies and Updates, 48 J. MED. CHEMISTRY
4111, 4111 (2005). CSAR dataset is 343 protein-ligand complexes with binding
affinity data. See Richard D. Smith et al., CSAR Benchmark Exercise of 2010:
Combined Evaluation Across All Submitted Scoring Functions, 51 J. CHEM.
INFO. & MODELING 2115, 2116 (2011) (“In this analysis, we are particularly
interested in the complexes that are consistently scored well versus those that
consistently scored poorly. GOOD complexes score within 1.1 pKd of the
experimental binding affinity for at least 12 of the 17 scoring functions
described below, and BAD must be outliers for 12 or more of the scoring
functions, see Figure 1. T”). Zilian & Sotriffer chose data involving three targets
only. Zilian & Sotriffer, supra note 226, at 1924.
227. See supra note 182 (illustrating regression).
228. A random decision forest is an AI model that operates by constructing
multiple decision trees. Tin Kam Ho, Random Decision Forests, in
PROCEEDINGS OF 3RD INTERNATIONAL CONFERENCE ON DOCUMENT ANALYSIS
AND RECOGNITION 278 (1995).
229. See supra notes 195–97 and accompanying text (introducing Pearson’s
coefficient).
230. Zilian & Sotriffer, supra note 226, at 1925.
231. Yang Li & Jianyi Yang, Structural and Sequence Similarity Makes a
Significant Impact on Machine-Learning-Based Scoring Functions for ProteinLigand Interactions, 57 J. CHEM. INFO. & MODELING 1007, 1007 (2017).
232. The pregnane X receptor (PXR), “also known as the steroid and
xenobiotic sensing nuclear receptor (SXR), is a promiscuous protein encoded by
the NR1I2 (nuclear receptor subfamily 1, group I, member 2) gene.” Huali Shi
et al., Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation
in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by
Using Naive Bayesian Classification Technique, 28 CHEM. RSCH. TOXICOLOGY
116, 116 (2015).
233. Id.
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will activate PXR is important in the virtual screening stage. Shi
et al. trained a Naive Bayesian classification AI model234 using
532 chemical compounds with known PXR activation activities
and achieved an AUC235 of 0.882.236 From the prediction results,
they also identified twenty important structural fragments as
favorable or unfavorable for PXR activation, demonstrating that
this AI not only makes great predictions, but also facilitates
people’s understanding of drug properties.237
2. Discovery and Design of New Drugs
a. De novo drug design
De novo drug design is “the design of novel chemical entities
that fit a set of constraints . . . .”238 The phrase “de novo”
indicates that one can generate undiscovered or non-existing
chemicals “without a starting template.” 239 The benefits of de
novo drug design include “the exploration of a broader chemical
space, design of compounds that constitute novel intellectual
property, the potential for novel and improved therapies, and the
development of drug candidates in a cost- and time-efficient
manner.”240 A good de novo drug design AI should produce drug
candidates that not only possess expected biological activities,
but also are “chemically diverse” and “contain similar (physico)
chemical properties to already known ligands.”241
New drugs against COVID-19. In response to the urgent
need to control the virus that causes COVID-19, the scientific
community has been actively looking for drugs against it. 242 For
234. Naive Bayes is an AI model that assumes the features of an input are
uncorrelated with each other. See generally David D. Lewis, Naive (Bayes) at
Forty: The Independence Assumption in Information Retrieval, in MACHINE
LEARNING: ECML-98, at 4 (1998).
235. See supra notes 186–90 and accompanying text (introducing AUC).
236. Shi et al., supra note 232, at 123–24.
237. Id. at 124.
238. Varnavas D. Mouchlis et al., Advances in De Novo Drug Design: From
Conventional to Machine Learning Methods, 22 INT’L J. MOLECULAR SCI. 1676,
1677 (2021) (citation omitted).
239. Id. (citation omitted).
240. Id.
241. Xuhan Liu et al., An Exploration Strategy Improves the Diversity of De
Novo Ligands Using Deep Reinforcement Learning: A Case for the Adenosine A2A
Receptor, 11 J. CHEMINFORMATICS, no. 35, 2019, at 2.
242. See Samuel Lalmuanawma et al., Applications of Machine Learning
and Artificial Intelligence for Covid-19 (SARS-CoV-2) Pandemic: A Review, 139
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instance, Chenthamarakshan et al. developed a generative
modeling framework243 based on a deep learning approach,244
CogMol.245 CogMol has been shown to produce compounds that
bind to at least one of three COVID-19-related target proteins of
the SARS-CoV-2 virus.246 When a drug binds a target protein,
the protein can no longer bind a cell in a human body and the
virus is thereby deactivated to some extent.247 Impressively,
among more than one-thousand compounds produced by
CogMol, 87% showed binding capabilities to at least one of the
three target proteins,248 and only thirty-nine are existing
compounds.249 Notably, some of the predicted existing
compounds are FDA-approved drugs for other purposes,250
which relates to drug repurposing, discussed below.
b. Drug Repurposing
Drug repurposing, or drug repositioning, refers to the
practice of finding new uses for approved drugs.251 It is “highly
attractive because of its potential to speed up the process of drug
development, hence reducing costs in addition to providing new
treatments for unmet medical needs.”252

CHAOS, SOLITONS & FRACTALS, Oct. 2020, at 1 (reviewing how AI and machine
learning were used to solve COVID-19-related problems).
243. “Generative classifiers learn a model of the joint probability, 𝑝(𝑥, 𝑦), of
the inputs 𝑥 and the label 𝑦, and make their predictions by using Bayes rules to
calculate 𝑝(𝑦|𝑥), and then picking the most likely label 𝑦.” Andrew Ng &
Michael Jordan, On Discriminative vs. Generative Classifiers: A Comparison of
Logistic Regression and Naive Bayes, in 14 ADVANCES IN NEURAL INFORMATION
PROCESSING SYSTEMS § 1 (2001). Using the Minnesota weather example, supra
note 182, a discriminative classifier might predict that the weather in
Minnesota tomorrow is cold, but a generative would predict that the probability
of cold weather tomorrow is 90%.
244. See generally Yann LeCun et al., Deep Learning, 521 NATURE 436
(2015).
245. Vijil Chenthamarakshan et al., CogMol: Target-Specific and Selective
Drug Design for COVID-19 Using Deep Generative Models, in 33 ADVANCES IN
NEURAL INFORMATION PROCESSING SYSTEMS 1 (2020).
246. Id. at 3.
247. See supra note 225 for introduction of antagonists.
248. Id. at 6–7.
249. Id. at 6 (“Only 19, 5, and 15 of the generated molecules match exactly
with an existing [compounds] . . . .”).
250. Id. at 3.
251. Francesco Napolitano et al., Drug Repositioning: A Machine-Learning
Approach Through Data Integration, 5 J. CHEMINFORMATICS, 2013, at 1, 2.
252. Id. at 1.
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New anti-cancer drugs. Napolitano et al. developed a novel
approach to find alternative uses for existing drugs.253
Specifically, the group trained an AI classifier to predict
therapeutic effects using thousands of FDA-approved drugs,254
and then applied it to 410 drugs, obtaining a classification
accuracy of 78%.255 The group claimed this accuracy is
adequately reliable to assist drug repurposing.256 In other words,
instead of treating mismatches between known and predicted
drug classifications as pure errors, the model was allegedly
reliable enough to allow people to interpret the mismatches as
hints for other therapeutic effects of the drugs.257 In conclusion,
with the assistance of AI, the group reported several existing
non-cancer-related drugs to have anticancer potential with
trackable mechanisms.258
3. Guiding Synthesis Process
In addition to knowing the composition and properties of
promising drug candidates, it is also important to know how to
synthesize them. An AI’s capability to predict chemical reactions
and design retrosynthesis routes allows people to rationally
synthesize new molecules.259 Reactions prediction proceeds in a
forward direction as “the task is to infer how a set of molecules
(starting materials) will react and what the product will be.”260
By contrast, retrosynthesis goes in a reverse direction, wherein
“the aim is to propose how to make a target molecule, by
deducing reactions where the target molecule is the product.”261
a. Reaction Prediction
New reactions from failures. To train an AI to predict
whether a given reaction will happen, training data must

253. Id. at 2.
254. Specifically, Napolitano et al. used gene expressions of 1265 drugs,
chemical structures of 6594 drugs, and biological targets of 1571 drugs to train
the model. The three databases had 410 drugs in common, which were later fed
into the classifier for repurposing. Id. at 2, 6.
255. Id. at 2–3.
256. Id.
257. Id.
258. Id. at 5.
259. See infra Sections II.B.3.a–b.
260. Segler & Waller, supra note 152, at 5966.
261. Id.
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include both successful and failed reactions.262 While successful
reactions can be obtained from published literature, “the failed
vast majority of unreported . . . reactions are archived in
laboratory notebooks that are generally inaccessible.”263
Realizing this problem, Raccuglia et al. trained an AI based on
the SVM model264 to predict whether a set of reactions will yield
inorganic-organic crystal products using not only the successful
experiment records, but also failed experiment records from
their own lab notebooks. 265 Surprisingly, the reaction
predictions achieved an accuracy of 89%, higher than the human
expert’s intuition accuracy rate of 78%.266 Interestingly, to
overcome the poor interpretability of SVM models 267 the group
used the training data and corresponding predictions to train a
decision tree,268 which is much easier to interpret. 269 This
innovative step allowed them to make plausible hypotheses
about the conditions that contribute to the success of reactions
and
revealed
“previously
unknown
insights
into . . . chemistry.”270
b. Retrosynthesis
Sophisticated route design. AI for retrosynthesis has been
criticized for containing easily recognizable “chemically
unreasonable steps.”271 Segler et al. attempted to solve this
problem with a two-part AI.272 First, the group trained an AI

262. See generally supra Section II.A.1 (introducing requirements for data
in AI developing processes).
263. Paul Raccuglia et al., Machine-Learning-Assisted Materials Discovery
Using Failed Experiments, 533 NATURE 73, 73 (2016).
264. A support vector machine (SVM) is an AI model that operates by finding
a hyperplane which best separates input data. See generally M. A. Hearst et al.,
Support Vector Machines, 13 IEEE INTEL. SYS. & THEIR APPL. 18 (1998).
265. Raccuglia et al., supra note 263, at 73.
266. Id. at 74.
267. See supra note 175.
268. A decision tree is a tree-like AI model, where each node of the tree
represents a test for making a decision, and edges below a node, if any, lead to
different consequences according to the test results. See generally J. R. Quinlan,
Induction of Decision Trees, 1 MACH. LEARNING 81 (1986).
269. Raccuglia et al., supra note 263, at 74.
270. Id. at 76.
271. Marwin H. S. Segler et al., Planning Chemical Syntheses With Deep
Neural Networks And Symbolic AI, 555 NATURE 604, 607 (2018).
272. Id. at 605.
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based on the Monte Carlo tree search (MCTS)273 using millions
of reactions.274 The first AI is able to produce synthesis routes
for a given molecule with a “top 50 accuracy”275 of 72.5%.276 The
group then trained a second AI based on a deep neural
network277 to predict whether the reactions of a synthesis route
recommended by the first AI would be feasible. 278 The final AI
integrates the first and second AIs to form the so-called “3NMCTS AI,” in which the routes recommended by the MCTS part
(the first AI) are filtered by the 3N part (the second AI, using a
total of three neural networks, hence “3N”). 279 The AI’s overall
performance reached a 92% problem solve rate within sixty
seconds, showing an incredible capacity for fast designing
synthesis routes.280 Circling back to the aforementioned
challenge, the group also performed a double-blind survey;281 the
result showed that experts did not prefer literature routes over
routes designed by the AI with any statistical significance.282

273. Monte Carlo tree search is a tree-like AI model that looks for most
promising next steps based on random sampling of the search space. See
generally Cameron B. Browne et al., A Survey of Monte Carlo Tree Search
Methods, 4 IEEE TRANSACTIONS ON COMPUTATIONAL INTEL. & AI GAMES 1
(2012).
274. Segler et al., supra note 271, at 604.
275. The “top 50 accuracy” is the percentage of results where the correct
route is among the top fifty recommended routes by the AI. See, e.g., Rushabh
Nagda, Evaluating Models Using the Top N Accuracy Metrics, NANONETS (Nov.
8, 2019), https://medium.com/nanonets/evaluating-models-using-the-top-naccuracy-metrics-c0355b36f91b.
276. Segler et al., supra note 271, at 605.
277. Deep neural network is an AI model that mimics the neural networks
in a human brain. See generally Yang et al., supra note 154, at 10531–32.
278. Similar to the challenge stated in Raccuglia et al., supra note 263,
Segler et al. also needed failed reactions as negative data to train the AI to
predict reaction feasibility. Segler et al., supra note 271, at 605. To solve this
problem, Segler et al. used “implicit information about reactions that do not
occur” from published reactions. Id. For example, for “a high-yielding reaction
A + B → C, [it can be assumed] that hypothetical products D, E, . . . are not
formed.” Id. Using this logic, the group obtained negative reactions by “shuffling
the associated pairs of products and corresponding reactions.” Id.
279. Id. at 605–06.
280. Id. at 607.
281. “Double-blind” means “neither the participants nor the conductors were
aware of the origin of the routes.” Id. Specifically, participants here were fortyfive graduate-level organic chemists from two world-leading organic chemistry
institutes in China and Germany. Id.
282. Id. Informally, this statement can be understood as it is possible that
the experts did not prefer literature routes statistically. See generally JEROME
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This work is impressive because it “can be initially set up within
a few days without the need for tedious and biased expert
encoding or curation[,] applicable to discipline-scale datasets,”
and the synthesis routes can be proposed in seconds and are noninferior to the ones designed by human experts.283
C. ACCESSIBILITY AND LIMITATION OF AI
While AI is making an irreplaceable contribution to R&D in
traditionally unpredictable arts, its impact on the general public
depends on whether the AI sources are accessible and whether
the resources are useful.
1. Accessibility
The accessibility of AI as a tool to the public relies on three
factors: open data, open software, and open education.284
a. Database
Data is one of the fundamental elements that allows
researchers to perform novel research and repurpose published
works.285 The scientific community has been striving to make
more data publicly accessible.286 Nowadays, there are more than
fifty material-related databases287 and more than forty drugrelated databases, 288 including millions of data entries for
L. MYERS ET AL., RESEARCH DESIGN AND STATISTICAL ANALYSIS 65–90 (3d ed.
2010).
283. Segler et al., supra note 271, at 609.
284. Butler et al., supra note 152, at 548.
285. See supra text accompanying notes 157–58.
286. Joanne Hill et al., Materials Science with Large-Scale Data and
Informatics: Unlocking New Opportunities, 41 MRS BULL. 399, 404 (2016) (“The
open-access (OA) paradigm, in which readers are able to view and (sometimes)
repurpose published research at no cost, is gaining traction as key stakeholders
jump on board. More publishers are adopting OA models, and increasing
numbers of papers are appearing under a creative commons license, which
makes content and data freely available. The Nature Publishing Group, for
example, launched the journal Scientific Data in 2014, which is OA and
dedicated specifically to redistributing important scientific data sets.”).
287. See id. at 402–03 tbl. I (listing notable materials data resources); Butler
et al., supra note 152, at 552 tbl. 3 (listing publicly accessible databases for
molecules and solids).
288. See Ruolan Chen et al., Machine Learning for Drug-Target Interaction
Prediction, 23 MOLECULES, no. 9, 2018, at 5–6, tbls. 1–2 (listing databases
supporting drug discovery methods and the statistics thereof); Wen Zhang et
al., Recent Advances in the Machine Learning-based Drug-target Interaction
Prediction, 20 CURRENT DRUG METABOLISM 194, at 194–97 (2019) (listing
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general and specific purposes, and the total data amount keeps
increasing.289 In addition to the organized databases, it is also
possible for researchers to extract data from publications. 290
b. Software and Education
There are a few freely available ML-based software
programs ready for use towards specific problems, 291 such as
AFLOW-ML for predicting electronic, thermal and mechanical
properties of materials,292 AdmetSAR 2 for predicting
absorption, distribution, metabolism, excretion, and toxicity of
drug candidates, 293 and AlphaFold for predicting 3D structures
of proteins.294 Many of these software programs can be used by
a simple “drag-and-drop” method, or by typing the descriptors of
compounds of interest.295
Motivated by the strong power of AI and its increasing
market, some corporations have formed to develop AI tools
according to clients’ needs.296 Other businesses have emerged to
databases for drug discovery); Andy H. Vo et al., An Overview of Machine
Learning and Big Data for Drug Toxicity Evaluation, 33 CHEM. RSCH.
TOXICOLOGY 20, 26 tbl. 3 (2019) (listing toxicity databases for drug safety
evaluation).
289. See Hill et al., supra note 286, at 406 (“The amount of data in the
materials community, as in many other areas of science and human endeavor,
is increasing exponentially . . . .”); Chen et al., supra note 288, at 4 (“Some of
these databases are being updated frequently, such as DrugBank, KEGG, and
STITCH . . . .”).
290. See, e.g., supra text accompanying notes 262–70, 278.
291. Dane Morgan & Ryan Jacobs, Opportunities and Challenges for
Machine Learning in Materials Science, 50 ANN. REV. MATERIALS RSCH. 71
supp. at 5–6 (2020) (listing machine learning software for material
engineering); Vo et al., supra note 288, at 24 tbl. 1 (listing machine learning
tools for extraction of molecular descriptors and fingerprints).
292. See generally Eric Gossett et al., AFLOW-ML: A RESTful API for
Machine-Learning Predictions of Materials Properties, 152 COMPUT.
MATERIALS SCI. 134 (2018).
293. See generally Hongbin Yang et al., admetSAR 2.0: Web-Service for
Prediction and Optimization of Chemical ADMET Properties, 35
BIOINFORMATICS 1067 (2019).
294. See, e.g., John Jumper et al., Highly Accurate Protein Structure
Prediction with AlphaFold, 596 NATURE 583 (2021) (stating that AlphaFold is
a network-based model that can predict “the 3d structure that a protein will
adopt based solely on its amino acid sequence”).
295. See, e.g., id.
296. See, e.g., AI software development for Chemistry and Materials R&D,
CHEMINTELLIGENCE,
https://chemintelligence.com/ai-software-development
(last visited Feb. 18, 2022) (advertising for “tailored AI software that accelerates
[clients] R&D”).
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provide assistance or cooperation using AI to aid in the research
process of their clients.297
Furthermore, thousands of papers presenting the
applications of AI to various scientific disciplines are published
every year.298 Many authors have made their accompanying
source codes open to the public along with their publications. 299
Accordingly, researchers can follow published AI methods and
adapt published codes, if available, in order to develop their own
AI.
Finally, there are plenty of educational resources available
for researchers with no AI background to learn how to develop
AI by themselves. 300 One can use a variety of programs to
develop AI,301 and numerous available machine learning
packages in different languages are making this even easier.302
2. Inaccessibility and Limitation
The availability of large quantities of data is what made AI
possible.303 Conversely, limiting access to data would limit the
application of AI. At present, available data is still less than
adequate for training AI in many scenarios, especially for drug
discovery purposes.304 Moreover, not all databases are freely

297. See Moe Elbadawi et al., Advanced Machine-Learning Techniques in
Drug Discovery, 26 DRUG DISCOVERY TODAY 769, 770 tbl. 1 (2021) (showing
“examples of pharmaceutical companies in which ML is central to their business
model”).
298. See Zachary J. Baum et al., Artificial Intelligence in Chemistry: Current
Trends and Future Directions, 61 J. CHEM. INFO. & MODELING 3197, 3198 fig. 1
(2021) (showing the number of chemistry publications using AI from 2000 to
2020); Morgan & Jacobs, supra note 204, at 73 fig. 1 (showing the number of
ML-related publications in material science and engineering from 2003 to
2019); Zhang et al., supra note 288, at 195 fig. 1 (showing the number of
publications related to machine learning and drug-target interactions from
2007 to 2017).
299. Mouchlis et al., supra note 238, at 1690 (arguing that “[s]haring of tools
and approaches, via an open innovation model, is [an] essential approach” to
facilitating the use of AI in research).
300. Butler et al., supra note 152, at 550 (listing education resources for
machine learning).
301. Lavecchia, supra note 175, at 328 tbl. 1 (listing programs that
implement machine learning processes).
302. Butler et al., supra note 152, at 550 tbl. 2 (listing publicly accessible
machine learning packages).
303. See supra Section II.B.
304. See, e.g., Mouchlis et al., supra note 238, at 1690–91 (“[I]t is well-known
that only a small fraction of the chemical space has been sampled in the search

714

MINN. J.L. SCI. & TECH.

[Vol. 23:2

available.305 Some useful data are never revealed to the public
and are instead carefully guarded as trade secrets. 306 To make
things worse, data in different disciplines are diversified in
format and available features. 307 Data obtained under different
conditions can differ significantly.308 A considerable portion of
existing data is not well annotated or is inaccessible.309 All of
this adds difficulty to research based on big data.
The expertise and skill required by the AI development
process also contributes to its inaccessibility. 310 For example, in
addition to the original information about chemicals, the
representation of chemicals impacts the performance of AI as
well.311 Counterintuitively, a more precise representation of
chemicals does not necessarily lead to better AI performance, as
higher precision may introduce more noise and make the data
pattern more complex for AI to recognize.312 Accordingly, finding
a representation that gives the best AI performance can be
tricky.
Lastly, although AI can be used to make predictions with a
high degree of accuracy, the potential factors underlying those
predictions cannot always be easily understood.313 To
for novel drug candidates.”); Wu et al., supra note 209, at 16 (“[T]he number of
cancer cell lines and drugs is limited, which may affect the model
generalizability in predicting novel drug combinations.”).
305. Hill et al., supra note 286, at 402–03 tbl. I (listing notable materials
data resources including free and non-free databases).
306. Id. at 405 (“Proprietary data exist in abundance, but many producers
of materials carefully guard their manufacturing data as trade secrets . . . .”).
307. See id. at 401 (“The current materials data landscape is a highly
fragmented patchwork quilt of smaller databases, each customized to present
information from a specific subdiscipline.”).
308. E.g., Vo et al., supra note 288, at 30 (“However, data integrated from in
vitro bioassays and in vivo studies can differ significantly between multiple
sources. Experimental design differences such as dosage, animal models used,
technologies used, or length of study can often give different or even conflicting
outcomes.” (citation omitted)).
309. Id.
310. See, e.g., supra Sections II.A.1–2.
311. See supra notes 163–67 and accompanying text.
312. Pedro J. Ballester et al., Does a More Precise Chemical Description of
Protein-Ligand Complexes Lead to More Accurate Prediction of Binding
Affinity?, 54 J. CHEM. INFO. MODELING 944, 945. (“[A] more precise chemical
description of the protein−ligand complex does not generally lead to a more
accurate prediction of binding affinity.”); id. at 952 (“[M]ore precise descriptors
often mean making modeling assumptions that introduce additional error.”).
313. E.g., Wu et al., supra note 209, at 16–17 (“Especially through [deep
learning] models, although they can get relatively accurate prediction results,

2022]

PATENTING THE "UNPREDICTABLE"

715

understand the physical, chemical, and/or biological
mechanisms behind AI prediction results, further research
might be needed.
III. USING AI PREDICTIONS IN PATENT PRACTICE
A. AI’S POTENTIAL OF FACILITATING PATENT PRACTICE UNDER
THE CURRENT LEGAL FRAMEWORK
Just as AI is helping significantly reduce the R&D cycle of
traditional unpredictable arts,314 it should also help reduce the
patent application cycle in these arts. This Section discusses how
patent practitioners can properly use AI predictions to enable
them to file applications early and safely.
1. A Recommended Practice
a. Rationally Tailor Claim Scope
Under current case law, by providing more guidance, a
patentee can always make his or her patent viewed more
favorably with respect to all Wands factors except the factor of
experimentation amount.315 That is, if experimentation is still
necessary for practicing a claim,316 the claim is not enabled if the
the potential factors affecting the prediction results cannot be understood.”);
Chen et al., supra note 288, at 11 (“[M]ost machine learning models possess
‘poor interpretability’ properties. In other words, it is difficult to understand the
underlying drug mechanism of action from a biological perspective.”).
314. See supra text accompanying note 208; see also Hill et al., supra note
286, at 399 (“[T]he potential impact of data-driven materials science is
tremendous: Materials informatics could reduce the typical 10–20 year
development and commercialization cycle 5 for new materials.”).
315. See supra Section I.A.1.
316. This is almost always true for AI-assisted patent applications in
technical fields where the art is traditionally unpredictable. Theoretically, an
AI can be 100% accurate, but only if it is designed for “a quite simple and
stationary problem.” Jose-Marcio, Why Can’t Machine Learning/Deep Learning
Algorithms Be a 100% Accurate at Test Time?, QUORA (June 23, 2019),
https://www.quora.com/Why-cant-machine-learning-deep-learning-algorithmsbe-a-100-accurate-at-test-time. Uncertainties in AI come from various sources,
including randomness in data collection, order of data observation, the
algorithm, sampling, and resampling. See Jason Brownlee, Embrace
Randomness in Machine Learning, MACH. LEARNING MASTERY (Aug. 12, 2019),
https://machinelearningmastery.com/randomness-in-machine-learning/.
Accordingly, AI for solving problems with a real-world value can hardly achieve
a 100% accuracy. Moreover, it is unclear how much predictability can release a
patentee from performing experiments. See discussion infra Section III.B
(discussing limitations of the existing legal framework).
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experimentation for practicing the claim exceeds a reasonable
amount, even if the experimentation is routine.317 Nevertheless,
one can only reduce the amount of experimentation by tailoring
the claim scope.318
Limiting the amount of experimentation is especially
pertinent where a claim includes functional limitations319 and
species that possess the claimed structural features far
outnumber those that also satisfy the functional limitations. 320
In such scenarios, a PHOSITA may need to perform a huge
amount of experimentation to find the species that possess both
functional and structural limitations out of those possessing
structural limitations only.321
To reduce the amount of (routine) experimentation, this
Note recommends using AI predictions to rationally tailor claims
similar to the hypothetical claim above, 322 which (1) specifies
more detailed functions and/or properties and (2) removes
species that are predicted to be unlikely to possess such
functions and/or properties. For example, instead of claiming
compounds for treating disease X, an applicant is better off
claiming compounds that have high binding affinities 323 to
biomolecular targets identified as related to disease X.
Using such a claiming approach has several advantages.
First, it fits the prediction capability of current AI.324 Inventing
a new drug for treating a disease is very complex.325 Few, if any,
317. See supra Section I.A.1.d.
318. Id.
319. See supra note 129 (introducing functional limitations).
320. See, e.g., Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149, 1162
(Fed. Cir. 2019) (holding the patent at issue was not enabled because “a
reasonable jury could only have found that at least many, many thousands of
[species] meet the structural limitations of claim 1, not all of which [meet the
functional limitation]”).
321. Id. (“[T]he ‘597 patent leaves a POSA searching for a needle in a
haystack to determine which of the ‘large number’ of 2’-methyl-up nucleosides
falls into the ‘small’ group of candidates that effectively treats HCV.”).
322. The hypothetical claim is reproduced here for convenience: A drug for a
disease X, consisting of a main structure M and an element attached to the main
structure M, wherein the element is A, B, or C. Arguments regarding this
hypothetical claim are applicable to any claim comprising structural and
functional limitations.
323. See supra notes 223, 225 (introducing binding affinity).
324. See supra Part II.C.1 (showing examples in which AI predict binding
affinities for certain molecules with satisfactory accuracy).
325. The extensive R&D cycles of a drug are a testament to the complexities
of drug development. See Jack W. Scannell et al., Diagnosing the Decline in
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AI have been developed for predicting whether a drug candidate
is effective for mitigating a given disease. Instead, AI are usually
developed for more specific purposes, such as predicting drug
binding affinities to a specific target, or the toxicity, absorption,
and metabolism of a drug.326 Second, it strengthens the claim
against potential indefiniteness rejections.327 The standard for a
drug to be effective against a certain disease is not necessarily
established in the art, but an applicant may need to define what
“effective” means in his or her application. 328 By contrast,
claiming compounds with a binding affinity higher than a
specified level is clear by itself, and a PHOSITA will be better
noticed of the metes and bounds of the claim. 329 Third, it satisfies

Pharmaceutical R&D Efficiency, 11 NATURE REVS. DRUG DISCOVERY 191 (2012)
(showing that drug developing processes are lengthy and costly). But in the
context of patent law, a drug may be regarded as useful for treating a disease
even if no human clinical trials have been performed. See supra note 111 and
accompanying text. Nevertheless, there may be more than one tractable
mechanism for treating a disease. See, e.g., supra text accompanying notes 242–
47. Therefore, it is much harder for a PHOSITA to experiment for whether a
compound is effective for a disease than for whether the compound has some
effects on a certain biomolecular target. See Idenix Pharms. LLC v. Gilead Scis.
Inc., 941 F.3d 1149, 1158 (Fed. Cir. 2019) (“Testing the compounds in the
specification alone for efficacy against HCV requires enough experimentation
for this factor to weigh in favor of non-enablement. Idenix relatedly argues that
a POSA would understand the ‘focus’ of the claim to be ‘the inhibition of the
NS5B polymerase’ to effectively cure HCV. Therefore, Idenix argues, a POSA
would know which candidates were likely to inhibit NS5B, and would test only
those, resulting in a ‘predictable and manageable’ group of candidate
compounds.” (citation omitted)).
326. See supra Section II.C.1 (presenting examples in which AI were
developed to predict specific properties of drug candidates).
327. 35 U.S.C. § 112(b) (1952) (“The specification shall conclude with one or
more claims particularly pointing out and distinctly claiming the subject matter
which the inventor or a joint inventor regards as the invention.” (emphasis
added)).
328. “[C]laim terms are typically given their ordinary and accustomed
meaning as understood by one of ordinary skill in the pertinent art.” Medrad,
Inc. v. MRI Devices Corp., 401 F.3d 1313, 1318 (Fed. Cir. 2005). But if there is
no established ordinary meaning for a term recited in a claim, the applicant
would have to clearly define it in the patent specification to avoid violating the
definiteness requirement. See, e.g., Icon Health & Fitness, Inc. v. Polar Electro
Oy, 656 F.App’x 1008, 1014–15 (Fed. Cir. 2016) (affirming indefiniteness of
claims reciting “in-band” and “out-of-band” communications because there were
no established meanings of “in-band” and “out-of-band” communications and
the patentee failed to define the terms either).
329. See McClain v. Ortmayer, 141 U.S. 419, 424 (1891) (“The object of [the
definiteness requirement] is not only to secure to him all to which he is entitled,
but to apprise the public of what is still open to them.”).
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the utility requirement. As stated above, an in vitro efficacy that
bears a correlation with in vivo efficacy satisfies the utility
requirement for a drug that is claimed to be effective for a certain
disease.330 Accordingly, the binding affinities provided by AI
predictions, which are more likely to be measured in vitro, are
sufficient to support the utility of the claimed compounds.331
Lastly, since the species predicted to be ineffective are removed
from the claim scope by the AI, the total species covered by the
claim will be much fewer.332 Fewer species mean less
unnecessary experimentation, which in turn helps the claim
pass the enablement requirement.333
b. Provide a Representative Number of Species
When AI learns a model from training data, it is learning
the pattern of the data.334 AI makes predictions based on the
learned pattern.335 Hence, molecules that are predicted to show
similar properties must possess similar features because all
predictions follow the same pattern. This means the predicted
results can necessarily be represented by a small portion of
them.336 Suppose that the claim scope has been rationally
330. See supra text accompanying note 111.
331. A drug’s binding affinity to a given target and the drug’s efficacy
against a disease related to the target are always closely correlated for
antagonists, but not for agonists. See supra note 225. If the drug to be patented
is an agonist, one should consider providing the drug’s efficacy to the target in
addition to the binding affinity so as to demonstrate that there is a satisfactory
correlation between the in vitro data and prospective effects in human bodies.
Id.
332. For example, if the patentee in Idenix Pharms. LLC v. Gilead Scis. Inc.
rationally tailored its claim as recommended, the claim would cover much fewer
species. 941 F.3d 1149, 1162 (Fed. Cir. 2019) (“[T]he [patent-at-issue] leaves a
POSA searching for a needle in a haystack to determine which of the ‘large
number’ of 2’-methyl-up nucleosides falls into the ‘small’ group of candidates
that effectively treats HCV.” (citations omitted)).
333. See supra Section I.A.1.d (demonstrating that under current case law,
the enablement requirement implicates the necessary experimentation for
practicing a claim cannot exceed a reasonable amount).
334. See supra Section II.A.2 (introducing the process of training AI).
335. See id. (introducing how AI makes predictions).
336. In many cases, one can find the pattern of predicted results by
observation. See, e.g., Stanev et al., supra note 183, at 9 tbl. 3 (listing compounds
predicted to have superconductivity potentials, where, for example, KSbO 2,
RbSbO2, and CsSbO2 are different in only one element, and the different
elements belong to the same chemical group). Concededly, there are cases where
the AI predictions are difficult to interpret. See supra text accompanying note
313. In such cases, one may consider extra strategies to extract common
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tailored according to AI predictions, as recommended above. One
may reasonably expect that species within the small portion will
possess enough similarity with some species in the remaining
portion and be diverse enough to cover substantial differences
among all species of the claimed genus, thus constituting a
representative number of species.337
One should then experimentally confirm whether the
representative species possess desired properties and/or
functions. Given that the scope of the genus claim has already
been rationally narrowed, experimentation on these
representative species should not cost significant time or
money.338 Alternatively, an applicant may as well refer to
experiment data of these species provided in publications, if
available. Supporting the representative species with
experimentally confirmed data is a safeguard against written
description challenges, according to current case law. 339
As a final note to this recommended practice: if the claim
covers species which are not available off the shelf, then the
patent disclosure should include guidance on how to make such
species. 340 The applicant may refer to available synthesis routes
listed in other publications, if any. If the claim covers de novo
compounds for which no experimentally confirmed synthesis
routes are available, the applicant may consider developing or
using an available AI to predict synthesis routes, and
confirming, theoretically and/or experimentally, that the
predicted routes are feasible. 341

features of the predicted results. See, e.g., Stanev et al., supra note 183, at 10;
Shi et al., supra note 232, at 120–21; Raccuglia et al., supra note 263, at 74.
337. See supra Section I.B.1 (describing the claiming tactic of a
“representative number of species”).
338. In addition to the fact that only a few species are covered by a rationally
tailored claim, the specific function/property recited in the claim can be
experimentally confirmed more easily than a general function of treating a
disease. See supra note 325.
339. See, e.g., Invitrogen Corp. v. Clontech Lab’ys, Inc., 429 F.3d 1052 (Fed.
Cir. 2005); Ex Parte Gleave, 2006 WL 6927761 (B.P.A.I. 2006).
340. See 35 U.S.C. § 112(a) (“The specification shall contain a written
description of the invention, and of the manner and process of making and using
it . . . .” (emphasis added)).
341. See supra Section II.B.3 for information about AI application in design
chemical synthesis routes.
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2. Alternative Options
a. Claim by Structure
It is also possible to use AI predictions to claim by structure,
without adding functional limitations. Nevertheless, this is not
necessarily a better way of claiming. Certainly, claiming by
structure is less susceptible to indefiniteness rejections, and
seems to be more easily enabled due to the lack of functional
limitation. 342 But the claim still has to satisfy the utility
requirement.343 Accordingly, if many species possessing the
recited structure do not show the identified utility, the claim will
still be found invalid for failing the utility requirement (and thus
the enablement requirement), unless a PHOSITA is able to
distinguish
the
operative
species
without
undue
experimentation—harkening back to the original enablement
issue.344
b. Incorporate AI Development as Part of the Guidance
Instead of claiming the end results of AI predictions, some
applicants might prefer to claim broadly and include AI
development as part of the guidance for enablement purposes. It
is outside the scope of this Note to assert which claiming
approach makes more business sense. Nevertheless, the
approach of claiming broadly and disclosing AI development
techniques makes less legal sense.
Courts would likely be more averse to this approach than
the recommended one because such claims are more likely to
overreach.345 Courts might be unable to invalidate such claims
under the enablement requirement if it can be shown that a
PHOSITA is able to follow the guidance to develop an AI with
good performance and if necessary experimentation is not undue
in view of AI predictions.346 Yet courts could still strike down the
claims based on the written description requirement. 347 AI is
likely, if not always, to provide predictions with some

342. See supra text accompanying notes 319–21.
343. See supra Section I.A.2.
344. Id.
345. See supra text accompanying notes 117–18.
346. See supra Section I.A.1 (discussing the Wands factors for constituting
undue experimentation).
347. See supra note 125.
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randomness.348 Hence, there is hardly any guarantee that the
list an applicant provides based on his or her own AI will
represent the species in the broad claim scope.349 If the opposing
party can produce evidence to this effect, the validity of the claim
is at risk.
3. A Flip Side: Obviousness?
While increased predictability makes a patent stronger
against enablement and written description requirements, it
may nevertheless render a patent weaker against obviousness
rejections.350 Non-obviousness is a statutory requirement for
patents under 35 U.S.C. § 103:
A patent for a claimed invention may not be obtained . . . if the
differences between the claimed invention and the prior art are such
that the claimed invention as a whole would have been obvious before
the effective filing date of the claimed invention to a person having
ordinary skill in the art to which the claimed invention pertains.351

For a claimed invention to be obvious, the invention must be
such that a PHOSITA can reasonably expect that the invention
will be successful, or in the languages of patent law, be operable
in view of the prior art.352 A reasonable expectation of success in
turn requires some predictability of the art. Consequently, the
predictability of an invention works against non-obviousness.353

348. See supra note 321.
349. If the claim scope has not been tailored according to the AI predictions,
then it is possible that the AI predictions missed one or more significant species
within the scope of the claim due to the inherent randomness of its
predictability model. See supra note 316 (discussing the inherent randomness
existing in most AI).
350. See generally David Tseng, Not All Patents Are Created Equal: Bias
Against Predictable Arts Patents in the Post-KSR Landscape, 13 CHI.-KENT J.
INTELL. PROP. 165 (2013) (arguing the decision of KSR Int’l. Co. v. Teleflex Inc.,
550 U.S. 398 (2007) and subsequent USPTO guidelines, infra note 353, made it
much easier for predictable art patents to be held obvious, even to an unfair
extent).
351. 35 U.S.C. § 103 (1952).
352. In re Merck & Co., 800 F.2d 1091, 1097 (Fed. Cir. 1986) (“[A] reasonable
expectation that the beneficial result will be achieved is necessary to show
obviousness.”).
353. See Examination Guidelines for Determining Obviousness Under 35
U.S.C. § 103 in View of the Supreme Court Decision in KSR International Co.
v. Teleflex Inc., 72 Fed. Reg. 57,526, 57,529 (Oct. 10, 2007) [hereinafter KSR
Guidelines] (listing seven rationales for finding obviousness, five of which
include predictability as a factor).
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So will an increase in predictability due to AI development
make inventions in the traditionally unpredictable arts more
susceptible to an obviousness challenge? It depends.
As discussed above, databases, AI software, and developing
tools are not equally accessible.354 For inventions that can be
created by freely available, easy-to-use databases and AI
software, there is a strong argument that the level of PHOSITA
is improved by the AI resources.355 For example, traditionally, to
determine the 3D structure of a protein, researchers have to first
crystallize a protein with a high purity and determine its
structure through various experiments.356 This process is timeconsuming and does not necessarily generate an accurate result,
as there can be errors made in each of the many steps of the
experiments.357 Now, this process can be performed by the AI
tool AlphaFold quickly and reasonably accurately.358 As a result,
any invention in which the only “inventive” part is the
knowledge of a protein structure may be rendered obvious, as
anyone having ordinary skills in biology and computing could
use AlphaFold to obtain the protein structure, unless AlphaFold
wrongly predicts a protein structure and a PHOSITA is
effectively taught away by the prediction.359 This is not to say
that a free, capable AI tool will necessarily kill a patent. There
are plenty of other ways to establish non-obviousness, including

354. See supra Part II.C.2 (discussing inaccessibility concerns with AI).
355. Again, a PHOSITA is a “hypothetical person who is presumed to be
aware of all the pertinent prior art.” See supra note 75 and accompanying text.
Freely available AI resources are in the public domain, which a PHOSITA is
presumed to be aware of. Id.
356. Determining Protein Structure, NEOS GUIDE, https://neos-guide.org
/content/protein-structure (last visited Jan. 26, 2022) (introducing the process
for determining the 3D structure of a protein).
357. See Jumper et al., supra note 294, at 583 (“Structural coverage is
bottlenecked by the months to years of painstaking effort required to determine
a single protein structure.”).
358. Id.
359. Teaching away is a common argument against obviousness. See, e.g.,
W.L. Gore & Assocs., Inc. v. Garlock, Inc., 721 F.2d 1540, 1551 (Fed. Cir. 1983)
(holding the claims at issue were not obvious because “the [prior] art as a whole
teaches the other way”). “A reference may be said to teach away when a person
of ordinary skill, upon reading the reference, would be discouraged from
following the path set out in the reference, or would be led in a direction
divergent from the path that was taken by the applicant.” In re Gurley, 27 F.3d
551, 553 (Fed. Cir. 1994).
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spotting a non-obvious problem360 and making non-obvious use
or improvement of the results given by the AI tool.
For problems that cannot be readily addressed by AI
resources, innovation and non-obviousness may exist in the
development process of AI. Overcoming the limitation of data361
can be an innovative starting point of a work.362 The overall AI
training method is also non-obvious because the representation
of data, choice of models, and process of finding parameters all
require expertise and insight into the problem at hand.363
Moreover, although some AI work by finding promising
candidates from a candidate pool specified by its developer,
which may constitute choosing from “a finite number of
identified, predictable solutions,”364 the challenging process of
narrowing down thousands or even millions of candidates cannot
be deemed to be obvious. Finally, AI is not guaranteed to find a
solution to a given problem,365 which provides another argument
against applying the “obvious to try” rationale to AI-assisted
inventions.366

360. See, e.g., Omeprazole Patent Litig. v. Apotex Corp., 536 F.3d 1361, 1380
(Fed. Cir. 2008) (finding a drug preparation process including coating
omeprazole with an inert material non-obvious, in which omeprazole was a
known drug, the inert material was known but had not been used for coating,
and the coating process was known, because “a person of ordinary skill in the
art would not have inferred from the [prior art] that a negative interaction
[between omeprazole and the available coating materials] would occur”).
361. See supra Part II.C.2 (discussing how data inaccessibility limits AI).
362. See supra note 163 and accompanying text (providing examples of
developers using innovative strategies to obtain more data).
363. See supra Section II.A (introducing a general workflow of AI).
364. See KSR Int’l. Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007) (“When there
is a design need or market pressure to solve a problem and there are a finite
number of identified, predictable solutions, a person of ordinary skill has good
reason to pursue the known options within his or her technical grasp. If this
leads to the anticipated success, it is likely the product not of innovation but of
ordinary skill and common sense.” (emphasis added)).
365. Yang et al., supra note 154, at 10538 (“One should keep in mind
that . . . the data sets used for machine learning in drug discovery do not
necessarily permit a solution to be found by the learning system.”).
366. The statement quoted in supra note 364 is now famously known as the
“obvious to try” rationale for finding obviousness. See KSR Guidelines, supra
note 353, at 57,529 (defining the “obvious to try” rationale).
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B. LIMITATIONS OF THE CURRENT LEGAL FRAMEWORK FOR AIASSISTED INVENTIONS
While this Note suggests that the recommended AI-assisted
practice described above367 is the best choice available to satisfy
the enablement and written description requirements with the
least amount of experimentation, it unavoidably involves some
uncertainties due to the limitations of the current legal
framework for AI-assisted inventions.
1. False Dichotomy: Predictable and Unpredictable Arts
Although “predictability” was initially used as a term of
degree in In re Fisher,368 later cases typically use it as a
qualitative term such that an art is either predictable or
unpredictable, and then treat the art with different criteria
accordingly.369 This poses an AI-assisted invention an
insuperable difficulty: If an AI is able to provide a solution with
a 70% accuracy for a given problem, is this art predictable or
unpredictable?
Instead of categorically determining an art as either
predicable or unpredictable, this Note proposes the
predictability of an art be described by its degree with respect to
the impact on the amount of necessary experimentation. After
all, the amount of necessary experimentation is what ultimately
matters for enablement purposes.370 For example, it is more
instructive to say that for a genus of compounds with a common
main structure, the property changed due to a given element
attached at a certain site can be predicted with a 70% accuracy.
The means that for a PHOSITA to be enabled to make and use
seven species covered by the genus claim, the PHOSITA is
expected to experiment with ten randomly selected species of the
genus. Therefore, describing the predictability in such a way
provides a more tangible sense of how the predictability factor
affects whether the necessary experimentation is undue.

367. See supra Section III.A.1 (providing this Note’s recommended
practices).
368. In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970).
369. See supra Section I.A.1.c. (citing cases that use predictability as a
qualitative term).
370. See In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993) (“[T]o be
enabling, the specification of a patent must teach those skilled in the art how to
make and use the full scope of the claimed invention without ‘undue
experimentation.’” (citations omitted)).
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2. Unreasonable Test: Reasonable Amount of Routine
Experimentation
But does a high predictability—say 99%—really help
enablement under current law? Of course, 99% accuracy is not
100% accuracy. For a PHOSITA to practice the full scope of the
claim, he or she would still need to experiment with all species
in order to screen out the 1% that do not work. If the total
number of covered species is large, say, ten thousand, with a
hundred that do not work, is this claim enabled or not? On one
hand, ten thousand experiments are too many according to
Gilead and Wyeth.371 On the other hand, the Wands court has
also commented that a success rate of 44% for an antibody
production method is “respectable” and enabling.372 The only
way to reconcile these cases is to notice that the success rate of
experimentation in Gilead and Wyeth were supposed to be low
or there was no clue of the success rate.373 It is the potential large
number of failed experiments that courts intend to police, not
the experiments themselves. Otherwise, for genus claims that
potentially cover inoperable species, to prohibit a large quantity
of routine experimentation is equivalent to prohibiting a claim
that is broad. But the breadth of a claim scope, by itself, is never
a reason for invalidity.
The test based on a total experimentation amount is also illsuited for how patents are practiced or infringed in the real
world. If a patentee or a licensee 374 would like to practice the
claimed invention, the patentee or licensee will likely practice
only a few species in their interest. Similarly, for a copier to exert
unjustifiable benefits from the disclosure of the patent, the
copier only needs to find a few species that allow its business.

371. See supra note 93.
372. In re Wands, 858 F.2d 731, 739 (Fed. Cir. 1988).
373. Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149, 1162 (Fed. Cir.
2019) (“[T]he [patent-at-issue] leaves a POSA searching for a needle in a
haystack to determine which of the ‘large number’ of 2’-methyl-up nucleosides
falls into the ‘small’ group of candidates that effectively treats HCV.” (citations
omitted)); Wyeth & Cordis Corp. v. Abbott Lab’ys, 720 F.3d 1380, 1385 (Fed.
Cir. 2013) (“Wyeth scientist confirmed the unpredictability of the art and the
ensuing need to assay each candidate by testifying that, ‘until you test
[compounds], you really can’t tell whether they work or not [i.e., have
antirestenotic effects].’”).
374. The term “licensee” here refers to a person or an entity that can legally
practice a patent under a patent license.
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There is no compelling reason for one to attempt to practice all
species covered by the claim at the same time.
It is obvious then that a more appropriate test is the average
experimentation amount expected for practicing a randomly
selected species. This test takes into account the effective
proportion of the claimed genus and better fits with the reality
of patent practice. It will not disrupt the expectations of the
patent practice community because this test gives the same
results should it be applied to past relevant cases. 375 More
importantly, if this test is accepted by the PTO and courts, it can
be claimed to a great certainty that the recommended AIassisted patent practice will meet the enablement requirement
given the present high accuracy of AI predictions.
C. DEFENSE OF AI-ASSISTED PATENT PRACTICE
1. This Practice Aligns with the Policy Purpose of Patent Law
As provided in the United States Constitution, patent law
has been developed to “promote the Progress of Science and
useful Arts, by securing for limited Times to Authors and
Inventors the exclusive Right to their respective Writings and
Discoveries . . . .”376 It is a device for incentivizing the disclosure

375. For example, if the experimentation success rate is expected to be low,
such as what happened in Gilead, the average experimentation amount needed
to find one effective species will be huge. Conversely, if the success rate is
expected to be high, for example, 44% as in the facts in Wands, one can expect
to perform about 1/0.44 ≅ 2.27 experiments to find one effective species–
obviously a small amount of experimentation. Moreover, just like the test based
on total experimentation amount considers scenarios where experiments can be
done in parallel, and where each species has to be synthesized before being
tested, the proposed test based on average experimentation can also takes these
scenarios into account. See Wands, 858 F.2d at 740 (“[I]n the monoclonal
antibody art it appears that an ‘experiment’ is not simply the screening of a
single hybridoma, but is rather the entire attempt to make a monoclonal
antibody against a particular antigen.”); Gilead, 941 F.3d at 1159 (“[M]any
candidate nucleosides would need to be synthesized before they could be
screened, as not all candidate nucleosides were available for purchase.”). If
experimentation can be done in parallel, then the average experimentation
amount is further compressed by a factor of the number of experiments that can
be done simultaneously. Similarly, if some or all species need to be synthesized
before testing, then the average experimentation amount should add the
average time for synthesis.
376. U.S. CONST. art. I, § 8, cl. 8.
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of innovations which might otherwise be kept secret or never
exist due to threats of easy copying and imitating. 377
However, the positive effects of patent law vary among
different industries.378 For example, “[i]n fast moving fields,
such as electronics, semiconductor, and telecommunications,
patents granted years after filing may be of ‘little value.’”379 In
contrast, empirical studies suggest that “patent protection was
judged to be essential for . . . pharmaceuticals and chemicals”
industries, among which, in pharmaceuticals industry, 65% of
inventions would not been introduced and 60% would not have
been developed but for the existence of patent law system.380
Accordingly, patent law is an essential mechanism to encourage
the chemical and pharmaceutical industries, both of which are
of the utmost importance to human welfare.
At the same time, the average cost of drug research and
development is higher than ever.381 As introduced above, current
case law of the enablement and written description
requirements is a great hurdle for genus claims in chemistry and
biology arts to stand valid and can be discouraging to innovation
in these industries.382 Nevertheless, this ramification is mostly
due to the large amount of prematurely-filed patents, and courts

377. See Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 150–
51 (1989) (“The federal patent system . . . embodies a carefully crafted bargain
for encouraging the creation and disclosure of new, useful, and nonobvious
advances in technology and design . . . .”); see also KEVIN J. HICKEY, CONG.
RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR CONGRESS (2020) (“The
patent system has long been viewed as important to encouraging American
innovation by providing an incentive for inventors to create. Without a patent
system, the reasoning goes, there would be little incentive for invention because
anyone could freely copy the inventor’s innovation.”).
378. See generally Edwin Mansfield, Patents and Innovation: An Empirical
Study, 32 MGMT. SCI. 173 (1986) (comparing different industries on how
important they find patent protection to be).
379. FED. TRADE COMM’N, TO PROMOTE INNOVATION: THE PROPER BALANCE
OF COMPETITION AND PATENT LAW AND POLICY 34–35 (2003) (citation omitted).
380. Mansfield, supra note 378, at 174–75; see also Bhaven N. Sampat, A
Survey of Empirical Evidence on Patents and Innovation, 19–20 (Nat’l Bureau
of Econ. Rsch., Working Paper No. 25383, 2018) (“The effects of patents on
innovation incentives are stronger in some sectors (pharmaceuticals, chemicals)
than others.”).
381. See generally Scannell et al., supra note 325, at 191 (explaining that
research and development costs have increased steadily).
382. See supra Part I (describing the enablement and written description
requirements and how they present hardship to genus claims in the
traditionally unpredictable arts).
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are resolved to strike down the prematurely-filed patents despite
the potential discouraging impacts. 383
Some have argued prematurely filed, or questionable
patents in general, stifle follow-up research and incur social
costs. 384 Presumably, such questionable patents are more
common in arts related to chemistry and biology than others
because the total experimentation from finding one effective
species to confirming a whole effective genus is usually huge in
these areas. Nevertheless, a claim is useful only if it covers
adequate variations.385 Filing a premature patent might be the
only affordable way for entities in these industries to secure a
bargaining chip against potential competitors.
AI is a gift from the latest development of big data
techniques and computer science.386 Its accurate predictions
allow the chemistry and biology industries to file enabling
patent applications without performing experiments on every
species. 387 AI can affordably enhance patent quality in the
traditionally unpredictable arts so that the negative impact of
questionable patents are reduced, and the patent incentives for
these arts can be restored to the “pre-Lilly” era.388
One might argue that the AI-assisted patent practice is
allowing a patent to be a more accurate “hunting license,”389 and

383. Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1353 (Fed. Cir.
2010) (“Ariad complains that [the written description requirement]
disadvantages universities to the extent that basic research cannot be
patented . . . . That is no failure of the law’s interpretation, but its intention.”).
384. FED. TRADE COMM’N, supra note 379, at 187–88 (reporting arguments
including “[i]f breadth is defined too broadly—that is, more broadly than is truly
enabled—products that should be free to compete instead will infringe, and
unwarranted market power may result,” and “broad initial patents may raise
significant problems for follow-on innovation”).
385. See supra text accompanying notes 22–24 (explaining that narrow
claims only provide limited protection, leading to an incentive to claim broadly).
386. See Yang et al., supra note 154, at 10521–23 (introducing the history of
AI).
387. See generally supra Part II (illustrating the potential utility of AI
technology for patent seekers in chemistry and biology).
388. Many have argued that the decision of Ariad Pharm., Inc. v. Eli Lilly &
Co., 598 F.3d 1336 (Fed. Cir. 2010) has heightened the enablement and written
description requirement for the traditionally unpredictable arts. See, e.g.,
Karshtedt et al., supra note 24, at 40–41.
389. Brenner v. Manson, 383 U.S. 519, 536 (1966) (“[A] patent is not a
hunting license. It is not a reward for the search, but compensation for its
successful conclusion.”); see also Ebrahim, supra note 44, at 596

2022]

PATENTING THE "UNPREDICTABLE"

729

unconfirmed predictions amount to “no more than a wish or
plan.”390 Such arguments ignore the fact that in the
recommended practice,391 at the very least the species deemed
representative of the whole claimed genus are experimentally
confirmed before filing the application. 392 Moreover, during the
training process, the AI’s accuracy is validated by comparing its
predictions with results from experiments.393 The proposed
practice reduces the total amount of experimentation in a
rational and reliable way. AI enables the traditionally
unpredictable arts to be more predictable, and thus these arts
enjoy a similar, though not the same, benefit of the traditionally
predictable arts.
2. Equity Concerns
Similar to other resources, while AI provides great benefits
to the scientific community at large, it may also disadvantage
solo inventors and small entities. 394 First, as discussed above,
some AI tools and databases are not free, 395 and large companies
have more financial resources to pay for them. Second, if
developing AI using free databases and development tools, solo
inventors and small entities are still disadvantaged because the
whole AI training process, though made accessible by a plethora
of educational resources, still requires significant expertise,
skills, and time to complete.396 A large company can afford to
hire a professional group to perform the development process in
a much shorter time. However, this is an unavoidable inequity

(“[C]omputational research has made experimentation a ‘hunting license.’”
(citation omitted)).
390. Eli Lilly, 598 F.3d at 1350 (citation and quotation mark omitted).
391. See supra Section III.A.1 (outlining recommended practices).
392. See supra Section III.A.1.b (recommending confirming AI prediction
with some experiments).
393. See supra Section II.A.3 (introducing AI evaluation processes).
394. FED. TRADE COMM’N, supra note 379, at 83 (“[Economists] contend,
large firms sponsoring considerable R&D can reduce the marginal costs of
innovation by using ‘more specialized resources;’ can spread the fixed costs of
any R&D over a wider base of output; can spread the risk of unsuccessful R&D
efforts by sponsoring many R&D projects simultaneously; and have access to
inexpensive investment capital, drawn from the firm itself or from capital
markets.” (citation omitted)).
395. See discussion supra Section II.C.2 (discussing limitations on
accessibility to some AI resources and tools).
396. Id.
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existing in all cost-barricaded resources.397 In an effort to reduce
the general inequity in the patent application process, the PTO
provides discounts to “small”398 and “micro”399 entities on
various fees for patent applications. 400
Specific to the potential unfairness caused by AI resources,
this Note recommends that non-free AI tools and databases be
removed from the toolkits of a PHOSITA, such that patents that
are enabled only by the aid of commercially available AI
resources should be considered non-enabled. Although this
policy would not completely eliminate inequality related to AI
resources, it would contribute to reducing it.
CONCLUSION
Under current case law, the enablement and written
description requirements pose considerable difficulties to genus
claims in the traditionally unpredictable arts. 401 Regardless,
many applicants are forced to file prematurely due to the need
to protect their invented species and guard themselves against
easy variations. 402 AI provides a promising solution to this
dilemma. Scientists have been able to develop numerous AI that
make reasonably accurate predictions for important problems in

397. See supra note 394.
398. A small entity is any business entity that (1) does not confer any rights
in the invention to an entity that does not qualify for the small entity status, 37
C.F.R. § 1.27, and (2) “[w]hose number of employees, including affiliates, does
not exceed 500 persons.” 13 C.F.R. § 121.802.
399. A “micro entity” is “an applicant who makes a certification that the
applicant—(1) qualifies as a small entity . . . ; (2) has not been named as an
inventor on more than 4 previously filed patent applications . . . ; (3) did not . . .
ha[ve] a gross income . . . 3 times the median household income . . . ;” and (4)
does not confer any rights in the invention to an entity that does not qualify for
the micro entity status, 35 U.S.C. § 123(a) (2011), or “an applicant who certifies
that—(1) the applicant’s employer . . . is an institution of higher education . . . ;
or (2) the applicant has [conferred his or her] ownership interest in the
particular applications to such an institution of higher education.” 35 U.S.C. §
123(d).
400. Leahy-Smith America Invents Act, 35 U.S.C.A. § 10(b) (2011) (“The
fees . . . for filing, searching, examining, issuing, appealing, and maintaining
patent applications and patents shall be reduced by 50 percent with respect to
the application of such fees to any small entity . . . , and shall be reduced by 75
percent with respect to the application of such fees to any micro entity . . . .”).
401. See supra Sections I.A.1.c, I.B (outlining difficulties posed by
enablement and written description requirements on genes claims in the
traditionally unpredictable arts).
402. See supra Section III.C.1 (explaining the rationale for premature filing).
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chemistry and biology.403 Accordingly, this Note recommends
that an applicant utilize AI predictions to rationally tailor the
claim scope by reciting specific properties and/or functions and
removing species that are unlikely to possess such properties
and/or functions.404 This Note further recommends that an
applicant confirm the representative members of the claimed
species by experiments.405 A disclosure which includes
experiment results of the presentative species, in addition to the
guidance for making and using the rationally tailored claim,
should satisfy the enablement and written description
requirements.406
Although AI provides excellent predictions for the
traditionally unpredictable arts, AI can hardly, if ever, be 100%
accurate.407 A predictability between zero and 100% cannot be
readily categorized as predictable or unpredictable.408 This
shows the traditional dichotomy between predictable and
unpredictable arts is inherently unable to encompass AIassisted inventions. Accordingly, this Note proposes to abandon
the coarse description of predictable and unpredictable arts, but
rather dive into what predictability means to the quantity of
necessary experimentation.409
Moreover, for technological areas that cannot be predicted
100% accurately by AI, which is almost always the case,
increased predictability does not reduce the total amount of
necessary experiments.410 Under current case law, if the total
amount of experiments is too great, regardless of any other
factors, the invention is not enabled.411 Hence, this Note argues
403. See supra Section II.B (presenting examples in which AI makes great
predictions for material engineering and drug discovery).
404. See supra Section III.A.1.a (outlining this Note’s recommended
tailoring practices within the claiming process).
405. See supra Section III.A.1.b (outlining further recommendations for
applicants).
406. See supra Section I (outlining enablement and written description
requirements).
407. See supra note 321 (explaining that AI tools can hardly be 100%
accurate).
408. See supra Section III.B.1 (arguing the dichotomy of predictable and
unpredictable arts is false).
409. Id.
410. See supra Section III.B.2 (discussing how increased predictability does
not reduce the total amount of necessary experiments).
411. See supra Section I.A.1.d (outlining difficulties posed by the “total
amount of experiment” standard).
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that the total amount of experiments standard is
unreasonable.412 Instead, this Note proposes a test based on the
average amount of necessary experiments to make and use a
randomly selected species. 413 If this test is adopted, AI
predictions could significantly reduce the average amount of
necessary experiments, contributing greatly to enabling an
invention.
This Note also argues the recommended patent practice
aligns with the policy goal of patent law: to promote
technological developments.414 Patents encourage inventions in
the chemical and pharmaceutical industries more than others.415
The AI-assisted patent practice allows applicants to file patent
applications after experimenting only some of the species of the
claimed genus, which helps increase the incentive to innovate.
The AI-assisted patent practice also does not circumvent the
enablement and written description requirements because the
reduced amount of experimentation is a result of rational choice,
as the technological know-how is sufficiently disclosed to the
public.416
Finally, this Note recommends non-free AI resources be
removed from the toolkit of a PHOSITA so as to reduce
inequity.417 If this recommendation is adopted, AI can continue
to bring the world enormous benefits with minimum inequity
concerns.

412. See supra Section III.B.2 (discussing the unreasonableness of the “total
amount of experiment” standard).
413. See id. (outlining this Note’s recommended alternatives to current
standard).
414. See supra Section III.C.1 (discussing patent law policy implications).
415. See id. (explaining the incentive to innovate created by patent rights).
416. See id. (explaining that the use of AI-assisted patent practice aligns
with overarching policy goals).
417. See supra Section III.C.2 (recommending the discontinuation of the use
of non-free AI resources from PHOSITA toolkits in the interest of reducing
resource inequity).

